News Releases


May 15, 2013 SIMPONI® (Golimumab) Receives FDA Approval For Ulcerative Colitis
May 13, 2013 Biosense Webster Reports Compelling Results from Ground-Breaking SMART-AF IDE Study on the Safety and Effectiveness of the THERMOCOOL® SMARTTOUCH™ Catheter
May 13, 2013 U.S. FDA Grants Priority Review to Simeprevir (TMC435) for Combination Treatment of Genotype 1 Chronic Hepatitis C
May 3, 2013 FDA Grants Premarket Approval (PMA) for the SEDASYS® System for Healthy Patients Undergoing Sedation During Routine Colonoscopy and EGD Procedures
May 2, 2013 Janssen and Johnson & Johnson to Provide Webcast Presentation of Simeprevir Phase 3 Clinical Data Presented at The International Liver Congress of the European Association for the Study of the Liver (EASL)
May 1, 2013 Daratumumab Receives Breakthrough Therapy Designation in Double Refractory Multiple Myeloma from U.S. Food and Drug Administration
Apr 26, 2013 Ethicon Launches Next Generation Energy Device at American Society of Colon and Rectal Surgeons' Annual Meeting
Apr 26, 2013 INCIVO® Receives Positive Opinion From The Committee For Medicinal Products For Human Use (CHMP) For Twice Daily Dosing For Treatment Of Genotype-1 Hepatitis C Virus
Apr 25, 2013 Johnson & Johnson Announces Dividend Increase of 8.2%
Apr 24, 2013 Janssen Submits Marketing Authorisation Application for Simeprevir (TMC435) to the European Medicines Agency for the Treatment of Adult Patients with Chronic Hepatitis C Genotype 1 or Genotype 4
Apr 23, 2013 Johnson & Johnson to Host Pharmaceuticals Business Review
Apr 23, 2013 Findings from Two Phase 3 Studies of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Genotype 1 Chronic Hepatitis C Patients
Apr 18, 2013 Johnson & Johnson Announces Sale of Elan American Depositary Shares to Elan
Apr 16, 2013 Johnson & Johnson Reports 2013 First-Quarter Results:
Apr 11, 2013 Johnson & Johnson to Webcast Annual Meeting of Shareholders
Apr 8, 2013 Ibrutinib Receives Third Oncology Breakthrough Therapy Designation from U.S. Food and Drug Administration
Apr 3, 2013 Next-Generation Circulating Tumor Cell Test Demonstrates High Efficiency and Accuracy in New Study
Mar 29, 2013 U.S. FDA Approves INVOKANA™ (Canagliflozin) for the Treatment of Adults with Type 2 Diabetes
Mar 28, 2013 Janssen Submits New Drug Application to U.S. FDA for Simeprevir (TMC435) for Combination Treatment of Adult Patients with Genotype 1 Chronic Hepatitis C
Mar 25, 2013 LifeScan Announces Voluntary Recall of All OneTouch® Verio®IQ Blood Glucose Meters
Mar 19, 2013 Johnson & Johnson to Host Analyst Conference Call on First-Quarter Results
Mar 12, 2013 Johnson & Johnson Announces Opening of London Innovation Centre
Mar 12, 2013 Cordis Acquires Flexible Stenting Solutions, Inc.
Mar 8, 2013 Janssen Launches EXPLORER, Global Cardiovascular Research Program, Beginning with Five New Studies in Patients with Unmet Medical Needs
Mar 7, 2013 Janssen Submits European Marketing Authorisation Application for Canagliflozin/Metformin Fixed-Dose Combination Therapy to Treat Patients with Type 2 Diabetes
Mar 4, 2013 FDA Issues Complete Response Letter for XARELTO® (rivaroxaban) for the Reduction of Cardiovascular Events in Patients with Acute Coronary Syndrome
Feb 25, 2013 Johnson & Johnson Comments on Venezuelan Currency Devaluation
Feb 22, 2013 Janssen Files First Regulatory Application for Simeprevir (TMC435) for the Treatment of Genotype 1 Hepatitis C Patients in Japan
Feb 20, 2013 Johnson & Johnson to Participate in 2013 Citi Global Health Care Conference
Feb 12, 2013 Ibrutinib Receives Two Oncology Breakthrough Therapy Designations from U.S. Food and Drug Administration
Feb 12, 2013 Follow-up Data Show ZYTIGA® Plus Prednisone Continues to Delay Progression of Metastatic Castration-Resistant Prostate Cancer in Patients without Prior Chemotherapy
Feb 6, 2013 Johnson & Johnson to Participate in 2013 Leerink Swann Global Health Care Conference
Feb 5, 2013 XARELTO® to be Studied with Factor Xa Inhibitor Antidote
Feb 4, 2013 Ethicon Receives 510(K) Clearance For Enseal® G2 Articulating
Jan 22, 2013 Johnson & Johnson Presents Growth Strategies for Medical Devices & Diagnostics Segment
Jan 22, 2013 Johnson & Johnson Reports 2012 Fourth-Quarter and Full-Year Results:
Jan 21, 2013 Cordis Corporation Announces Two-Year Results from the STROLL Trial
Jan 18, 2013 Biosense Webster Showcases Cutting Edge Innovation at Boston AF 2013
Jan 17, 2013 Veridex and LabCorp Agreement Brings CellSearch CTC Test to China
Jan 11, 2013 Zytiga® Approved In the EU For Use In The Treatment Of Metastatic Castration-Resistant Prostate Cancer Before Chemotherapy
Jan 10, 2013 FDA Advisory Committee Recommends Approval of Canagliflozin for Treatment of Adults with Type 2 Diabetes
Jan 2, 2013 Johnson & Johnson Announces Quarterly Dividend for First Quarter 2013
Dec 31, 2012 FDA Grants Accelerated Approval for SIRTURO™ (bedaquiline) as Part of Combination Therapy to Treat Adults with Pulmonary Multi-Drug Resistant Tuberculosis
Dec 27, 2012 New Category I CPT Codes and Payment Rates for Circulating Tumor Cell Testing Effective January 1
Dec 21, 2012 Johnson & Johnson to Host Analyst Meeting to Discuss Fourth-Quarter/Full-Year 2012 Financial Results and Medical Devices and Diagnostics Review
Dec 12, 2012 Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin/Metformin Fixed-Dose Combination Therapy to Treat Patients with Type 2 Diabetes
Dec 12, 2012 CellSearch® 'Liquid Biopsy' Approved for Breast Cancer Patients in China
Dec 12, 2012 The New England Journal of Medicine Publishes Efficacy Data for ZYTIGA® Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer in Patients Who Have Not Received Chemotherapy
Dec 11, 2012 Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, in Relapsed/Refractory Mantle Cell Lymphoma Presented at American Society of Hematology Annual Meeting
Dec 10, 2012 FDA Approves Prescribing Information Update for EDURANT® (rilpivirine) to Include 96-Week Data in HIV-1-Infected Treatment-Naive Adult Patients
Dec 10, 2012 U.S. FDA Approves Expanded ZYTIGA® Indication For Treatment Of Metastatic Castration-Resistant Prostate Cancer
Dec 7, 2012 FDA Approves EVARREST™ Fibrin Sealant Patch
Dec 6, 2012 Janssen Submits Applications Requesting Approval Of Stelara® In U.S. And Europe
Dec 5, 2012 New Long-Term Study Suggests Lower Mortality in Alzheimer's Patients Treated with Galantamine Versus Placebo
Nov 30, 2012 CEO Alex Gorsky Elected Chairman of Johnson & Johnson; Bill Weldon To Step Down After 41-year Career at Johnson & Johnson
Nov 28, 2012 FDA Advisory Committee Recommends Accelerated Approval of Investigational Multi-Drug Resistant Tuberculosis Treatment Bedaquiline
Nov 19, 2012 Zytiga® Receives Positive Regulatory Recommendation in the European Union for Treatment of Metastatic Castration-Resistant Prostate Cancer before Chemotherapy
Nov 15, 2012 Janssen Research & Development Announces Establishment of Global Cross-Pharmaceutical Clinical Trial Investigator Databank
Nov 12, 2012 New Phase 3 Findings Show Stelara® Significantly Reduced Signs And Symptoms Of Active Psoriatic Arthritis
Nov 12, 2012 Phase 3 Data Show Intravenous Golimumab Inhibited Radiographic Progression In Patients With Active Rheumatoid Arthritis
Nov 10, 2012 Efficacy and Safety Data from Phase 2B Trials of Janssen's Simeprevir in Hepatitis C Patients with Advanced Fibrosis of the Liver Presented at Annual Meeting of the American Association for the Study of Liver Diseases
Nov 9, 2012 Health Care Executive, Scholar and Vice Chancellor from UCLA, Dr. A. Eugene Washington, Appointed to Johnson & Johnson Board of Directors
Nov 9, 2012 Phase 3 Results Show Canagliflozin as Add-On Therapy to Metformin and Pioglitazone Significantly Lowers Blood Sugar Levels in Adult Patients with Type 2 Diabetes
Nov 9, 2012 FDA Approves New 800mg PREZISTA® (darunavir) Tablet
Nov 8, 2012 S.M.A.R.T.® Vascular Stent Systems Receive FDA Approval for Use in SFA
Nov 7, 2012 Johnson & Johnson to Participate in Credit Suisse 2012 Healthcare Conference
Nov 2, 2012 Janssen and Johnson & Johnson to Provide Webcast Presentation of Immunology Pivotal Phase 3 Data Being Presented at the American College of Rheumatology Annual Meeting
Nov 2, 2012 FDA Approves XARELTO® (rivaroxaban) to Treat Deep Vein Thrombosis and Pulmonary Embolism, and to Reduce the Risk of Recurrent Events
Oct 30, 2012 Johnson & Johnson Postpones Medical Devices & Diagnostics Review
Oct 25, 2012 Johnson & Johnson to Host Medical Devices & Diagnostics Review
Oct 23, 2012 SAPPHIRE Worldwide Study Data Presented at TCT 2012
Oct 22, 2012 New One-Year Phase 3 Study Results Show Anti-TNF SIMPONI® Maintained Clinical Response In Treatment Of Moderately To Severely Active Ulcerative Colitis
Oct 17, 2012 Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2012
Oct 16, 2012 Johnson & Johnson Reports 2012 Third-Quarter Results:
Oct 10, 2012 Cordis Corporation Announces One-Year Results from the STROLL Trial
Oct 2, 2012 First Results from Phase 3 CANVAS Trial Show Canagliflozin as Add-on Therapy to Insulin Lowered Blood Sugar Levels in Patients with Type 2 Diabetes at an Elevated Risk for Cardiovascular Disease
Oct 1, 2012 Janssen Announces Worldwide Agreement To Develop And Commercialize JAK Inhibitor For Immunological Diseases
Sep 28, 2012 DACOGEN® Approved in the European Union for the Treatment of Acute Myeloid Leukaemia
Sep 28, 2012 Subcutaneous Velcade® Approved In The EU For The Treatment Of Multiple Myeloma
Sep 26, 2012 Janssen and Johnson & Johnson to Present Latest Phase 3 Results for Canagliflozin in the Treatment of Patients with Type 2 Diabetes
Sep 26, 2012 Notice of Postponement of Final Settlement Hearing to October 18, 2012, and Notice of Revised Settlement Objection Deadline of October 5, 2012 for Shareholders Who Received Mailed Notice after September 1, 2012
Sep 25, 2012 Janssen Research & Development to Present Latest Phase 3 Results for Canagliflozin in the Treatment of Patients with Type 2 Diabetes
Sep 18, 2012 Janssen Submits Application To FDA Requesting Approval Of SIMPONI® Intravenous Formulation For Treatment Of Moderately To Severely Active Rheumatoid Arthritis
Sep 18, 2012 Johnson & Johnson Announces Plans to Establish Innovation Centers
Sep 18, 2012 Johnson & Johnson to Host Analyst Conference Call on Third-Quarter Results
Sep 13, 2012 Sandra E. Peterson to Join Johnson & Johnson as Group Worldwide Chairman and Member of the Executive Committee
Sep 7, 2012 Janssen Research & Development Submits Complete Response to the U.S. FDA on XARELTO® (rivaroxaban) for the Reduction of Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome
Sep 5, 2012 Johnson & Johnson to Participate in Morgan Stanley Global Health Care Conference
Sep 5, 2012 U.S. FDA Grants Priority Review to Bedaquiline (TMC207) for Multi-Drug Resistant Tuberculosis Treatment
Aug 31, 2012 Janssen-Cilag International NV (Janssen) Submits European Marketing Authorisation Application for Investigational Multi-Drug Resistant Tuberculosis Treatment Bedaquiline
Aug 30, 2012 Janssen Pharmaceuticals, Inc. announces RISPERDAL® consumer protection settlement with 36 states and the District of Columbia
Aug 30, 2012 Janssen Biotech Announces Global License and Development Agreement for Investigational Anti-Cancer Agent Daratumumab
Aug 29, 2012 FDA Approves NUCYNTA® ER (tapentadol) Extended-Release Oral Tablets for the Management of Neuropathic Pain Associated with Diabetic Peripheral Neuropathy
Aug 29, 2012 U.S. FDA Grants Priority Review Of ZYTIGA® (Abiraterone Acetate) sDNA For Treatment Of Metastatic Castration-Resistant Prostate Cancer Before Chemotherapy
Aug 23, 2012 Janssen Announces Initiation Of Phase 3 Development Program For Sirukumab In Rheumatoid Arthritis
Aug 6, 2012 Johnson & Johnson Announces Discontinuation of Phase 3 Development of Bapineuzumab Intravenous (IV) in Mild-to-Moderate Alzheimer's Disease
Jul 19, 2012 Notice of Proposed Settlement of Derivative Actions, Final Settlement Hearing, and Right to Appear
  Stipulation and Agreement of Settlement
Jul 19, 2012
Jul 17, 2012 Johnson & Johnson Reports 2012 Second-Quarter Results: Sales of $16.5 Billion decreased 0.7% Versus 2011 Second Quarter; Second-Quarter EPS was $0.50 Excluding Special Items, 2012 Second-Quarter EPS of $1.30 increased 1.6%*
Jul 16, 2012 Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2012
Jul 16, 2012 Janssen Submits Applications Requesting Approval of Simponi® In U.S. And Europe for Treatment of Moderately to Severely Active Ulcerative Colitis
Jul 10, 2012 Janssen Licenses Diabetes Research Programs From Evotec and Harvard University
Jul 9, 2012 U.S. FDA Grants Priority Review for XARELTO® (rivaroxaban) Supplemental NDAs for the Treatment of Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), and the Long-Term Prevention of Recurrent DVT and PE
Jul 2, 2012 Janssen Research & Development Submits New Drug Application to FDA for Investigational Multi-Drug Resistant Tuberculosis Treatment Bedaquiline (TMC207)
Jun 28, 2012 Janssen Acquires Corimmun
Jun 26, 2012 Janssen Submits European Marketing Authorisation Application for Canagliflozin in Type 2 Diabetes
Jun 26, 2012 VELCADE® Receives Positive Regulatory Recommendation in the European Union for Subcutaneous Administration
Jun 21, 2012 FDA Issues Complete Response Letter for XARELTO® (rivaroxaban) for the Reduction of Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome
Jun 18, 2012 Johnson & Johnson to Host Analyst Conference Call on Second-Quarter Results
Jun 15, 2012 Janssen Submits Additional Marketing Applications for ZYTIGA® in the U.S. and European Union
Jun 14, 2012 Johnson & Johnson Announces Completion of Synthes Acquisition
Jun 12, 2012 Johnson & Johnson Receives U.S. Regulatory Clearance for Synthes Acquisition; Closing Date for Transaction Set
Jun 10, 2012 Positive Results from First Human Clinical Trials of a First-Generation Artificial Pancreas System is Significant Step Forward for Millions with Type 1 Diabetes
Jun 9, 2012 Canagliflozin Provided Substantial and Sustained Glycemic Improvements as Monotherapy and in Add-On Combinations in Adults with Type 2 Diabetes in Five Phase 3 Studies
Jun 8, 2012 Johnson & Johnson Expects to Incur Special Charge in Second Quarter for Previously Disclosed Legal Matters
Jun 6, 2012 New STELARA® Five-Year Data Show Consistent Efficacy and Safety Profile in Treatment of Moderate to Severe Plaque Psoriasis
Jun 5, 2012 Janssen and Johnson & Johnson to Present Results from Five Pivotal Phase 3 Studies Evaluating Investigational Canagliflozin for the Treatment of Type 2 Diabetes
Jun 5, 2012 New Phase 3 Data Show Stelara® Significantly Reduced Signs and Symptoms of Active Psoriatic Arthritis
Jun 5, 2012 New Phase 3 Data Show Simponi® Intravenous Formulation Significantly Improved Rheumatoid Arthritis Signs and Symptoms in Patients with Active Disease
Jun 2, 2012 ZYTIGA® Plus Prednisone Show Improvements in Asymptomatic or Mildly Symptomatic Chemotherapy-Naive Patients with Metastatic Castration-Resistant Prostate Cancer
May 31, 2012 Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin to Treat Patients with Type 2 Diabetes
May 29, 2012 FDA Issues Complete Response Letter for 800mg PREZISTA® (darunavir) Tablet
May 25, 2012 Janssen and Johnson & Johnson to Provide Webcast Presentation of ZYTIGA® (abiraterone acetate) Phase 3 Clinical Data Presented at the American Society of Clinical Oncology Annual Meeting
May 23, 2012 FDA Advisory Committee Recommends Against Approval of Oral Anticoagulant XARELTO® to Reduce the Risk of Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome
May 21, 2012 New Phase 3 Study Results Show Anti-Tnf Simponi® Induced Clinical Response in Adults with Moderately to Severely Active Ulcerative Colitis
May 17, 2012 Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN)
May 9, 2012 Janssen Research & Development Submits Supplemental New Drug Application to U.S. FDA for XARELTO(R) (rivaroxaban) to Reduce the Risk of Stent Thrombosis in Patients with Acute Coronary Syndrome
May 2, 2012 Johnson & Johnson to Participate in 2012 Deutsche Bank Securities, Inc. 37th Annual Health Care Conference
May 2, 2012 Johnson & Johnson (China) Investment Ltd. Acquires Guangzhou Bioseal Biotech Co., Ltd.
May 2, 2012 Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism
Apr 26, 2012 Johnson & Johnson Holds 2012 Annual Meeting of Shareholders
Apr 26, 2012 Johnson & Johnson Announces Dividend Increase of 7.0%
Apr 19, 2012 Johnson & Johnson to Webcast Annual Meeting of Shareholders
Apr 17, 2012 Johnson & Johnson Reports 2012 First-Quarter Results:
Apr 10, 2012 Johnson & Johnson to Host Analyst Conference Call on First-Quarter Results
Apr 9, 2012 Johnson & Johnson Announces Resignation of Sheri S. McCoy
Mar 28, 2012 Ortho-Clinical Diagnostics, Inc. Announces Availability of HTLV-I/II Assay
Mar 27, 2012 FDA Approves INTELENCE® (etravirine) Tablets for Treatment-Experienced Pediatric Patients with HIV-1, Following Priority Review
Mar 26, 2012 XARELTO® (rivaroxaban) Demonstrates Comparable Efficacy to Standard of Care for the Treatment and Secondary Prevention of Venous Blood Clots in Patients with Symptomatic Pulmonary Embolism in Pivotal Phase 3 Study
Mar 19, 2012 Johnson & Johnson to Provide Webcast Presentation of XARELTO® (rivaroxaban) Phase 3 Clinical Data Presented at the American College of Cardiology's Annual Scientific Sessions
Mar 8, 2012 Study Unblinded: ZYTIGA® (abiraterone acetate) Plus Prednisone for Asymptomatic or Mildly Symptomatic Chemotherapy-Naïve Patients with Metastatic Castration-Resistant Prostate Cancer
Feb 28, 2012 Johnson & Johnson to Participate in Cowen and Company 32nd Annual Health Care Conference
Feb 27, 2012 U.S. FDA Grants Priority Review for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome
Feb 21, 2012 Alex Gorsky to Succeed Bill Weldon as CEO of Johnson & Johnson
Feb 17, 2012 McNeil Consumer Healthcare Announces Voluntary Nationwide Recall of Infants' TYLENOL® Oral Suspension, 1 oz. Grape Due to Dosing System Complaints
Feb 9, 2012 Johnson & Johnson to Participate in 2012 Leerink Swann Global Health Care Conference
Jan 24, 2012 Johnson & Johnson Reports 2011 Fourth-Quarter and Full-Year Results:
Jan 17, 2012 Johnson & Johnson to Host Analyst Meeting to Discuss Fourth-Quarter and Full-Year 2011 Financial Results
Jan 3, 2012 Johnson & Johnson Announces First-Quarter 2012 Quarterly Dividend
Dec 29, 2011 Janssen Research & Development Submits Application to U.S. FDA for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome
Dec 8, 2011 Janssen Biotech, Inc. Announces Collaborative Development and Worldwide License Agreement for Investigational Anti-Cancer Drug, PCI-32765
Nov 28, 2011 Johnson & Johnson to Participate in the Piper Jaffray 23rd Annual Health Care Conference
Nov 28, 2011 EDURANT® (Rilpivirine) Approved in Europe for Treatment-Naïve Adults with HIV-1 Infection with a Baseline Viral Load ≤ 100,000 HIV-1 RNA Copies/mL
Nov 13, 2011 Landmark Study Shows that Adding Rivaroxaban to Standard Antiplatelet Therapy Significantly Reduced Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome
Nov 10, 2011 Ethicon Endo-Surgery Receives 510(K) Clearance for New ENSEAL® G2 Curved and Straight Tissue Sealers Line--Broadest Range of Advanced Bipolar Tissue Sealers Available for Open and Minimally Invasive Surgery
Nov 7, 2011 New Sirukumab (CNTO 136) Phase 2 Data Show Efficacy of Interleukin-6 Inhibitor Across Multiple Dose Regimens in Treatment of Rheumatoid Arthritis
Nov 5, 2011 INCIVO® (Telaprevir) Demonstrates Efficacy and Increased Cure Rates among Cirrhotic Patients with Genotype-1 Chronic HCV Compared to Standard of Care
Nov 5, 2011 Tibotec to present final safety and efficacy results from phase 2b PILLAR study of Once-daily TMC435 in late-breaker at AASLD
Nov 4, 2011 Ethicon-Endo Surgery Completes Acquisition of SterilMed
Nov 4, 2011 FDA Approves XARELTO® (rivaroxaban) to Reduce the Risk of Stroke and Systemic Embolism in Patients with Nonvalvular Atrial Fibrillation
Oct 31, 2011 Supplemental New Drug Application Submitted to FDA for NUCYNTA® ER (Tapentadol) Extended-Release Tablets for Diabetic Peripheral Neuropathic Pain
Oct 21, 2011 Johnson & Johnson Announces Fourth-Quarter 2011 Quarterly Dividend
Oct 21, 2011 FDA Approves Label Update for PREZISTA® to Include 192-Week Data in HIV-1-Infected Adult Patients Starting Treatment
Oct 18, 2011 Johnson & Johnson Reports 2011 Third-Quarter Results
Oct 11, 2011 Johnson & Johnson to Host Analyst Conference Call on Third-Quarter Results
Oct 5, 2011 Scios Inc. Announces Agreement with Department of Justice Regarding NATRECOR®
Sep 28, 2011 McNEIL-PPC, Inc. Acquires Full Ownership of the Johnson & Johnson-Merck Consumer Pharmaceuticals Co. Joint Venture
Sep 28, 2011 Ethicon Endo-Surgery to Acquire SterilMed
Sep 23, 2011 REMICADE® Receives FDA Approval as First Biologic Treatment for Pediatric Ulcerative Colitis
Sep 23, 2011 EDURANT® (rilpivirine) Receives Positive Opinion from the Committee for Medicinal Products for Human Use (CHMP) for Use in Treatment-Naïve Adults with HIV-1
Sep 20, 2011 INCIVO® (TELAPREVIR) Approved in Europe Offering Higher Cure Rates for Genotype-1 Chronic Hepatitis C Compared to Standard Treatment
Sep 9, 2011 FDA Issues Complete Response Letter to Janssen Biotech, Inc. for SIMPONI® Supplemental Biologics License Application
Sep 8, 2011 FDA Advisory Committee Recommends Approval of Oral Anticoagulant Rivaroxaban for the Prevention of Stroke and Systemic Embolism in Patients with Non-Valvular Atrial Fibrillation
Sep 7, 2011 ZYTIGA® Approved in the European Union for Metastatic Castration-Resistant Prostate Cancer
Sep 6, 2011 Johnson & Johnson to Participate in Morgan Stanley Global Health Care Conference
Sep 1, 2011 Young Patients to Benefit from Health Canada Approval of Remicade®* for Treatment of Pediatric Ulcerative Colitis
Aug 26, 2011 NUCYNTA® ER (tapentadol extended-release tablets) Receives FDA Approval for the Management of Moderate to Severe Chronic Pain
Aug 19, 2011 DePuy Orthopaedics Receives FDA 510(K) Clearance for TRUMATCH ® Personalized Solutions for TRUMATCH® Personalized Solutions
Jul 28, 2011 Mcneil Consumer Healthcare Announces Plans for New Dosing Instructions for TYLENOL® Products
Jul 28, 2011 ZYTIGA™* (Abiraterone Acetate) Receives Health Canada Approval for Treatment of Metastatic Prostate Cancer
Jul 22, 2011 FDA Issues Complete Response Letter to Janssen Biotech, Inc. for SIMPONI® Supplemental Biologic License Application
Jul 22, 2011 INCIVO® Receives Positive Opinion from the Committee for Medicinal Products for Human Use (CHMP) for the Treatment of Genotype-1 Hepatitis C Virus (HCV)
Jul 22, 2011 ZYTIGA® Receives Positive Regulatory Recommendation in the European Union for Treatment of Metastatic Castration Resistant Prostate Cancer
Jul 21, 2011 FDA Advisory Committee Recommends Approval of REMICADE® for Treatment of Pediatric Ulcerative Colitis
Jul 19, 2011 Johnson & Johnson Reports 2011 Second-Quarter Results:
Jul 19, 2011 EDURANT™ 96-Week Phase 3 Safety And Efficacy Data Presented At International Aids Society Conference
Jul 18, 2011 Johnson & Johnson Announces Third-Quarter 2011 Quarterly Dividend
Jul 17, 2011 Cilag GmbH International Completes Acquisition of Over-The-Counter Brands of J B Chemicals & Pharmaceuticals Limited
Jul 15, 2011 Janssen Pharmaceuticals, Inc. Announces Definitive Agreement To Divest Ortho Dermatologics Division
Jul 12, 2011 Johnson & Johnson to Host Analyst Conference Call on Second-Quarter Results
Jul 7, 2011 Janssen Pharmaceutica NV Completes Divestiture of Animal Health Business to Elanco, a Division of Eli Lilly And Company
Jul 1, 2011 FDA Approves XARELTO® (rivaroxaban tablets) to Help Prevent Deep Vein Thrombosis in Patients Undergoing Knee or Hip Replacement Surgery
Jun 28, 2011 Mcneil Consumer Healthcare Announces Voluntary Recall of One Product Lot of TYLENOL® Extra Strength Caplets 225 Count Distributed In the U.S.
Jun 28, 2011 Tibotec Pharmaceuticals Announces Agreement With Gilead Sciences to Develop and Commercialize a New Fixed-Dose Combination Of PREZISTA® and Cobicistat
Jun 17, 2011 Ortho-McNeil-Janssen Pharmaceuticals, Inc. Voluntarily Recalls One Lot of RISPERDAL® Tablets and One Lot of Risperidone Tablets
Jun 15, 2011 Johnson & Johnson Announces Special Charge Related to Restructuring Plans for Cordis Corporation Subsidiary
Jun 15, 2011 Cordis Announces Discontinuation of NEVO™ Sirolimus-Eluting Coronary Stent
Jun 14, 2011 Former Chairman and CEO of Aetna Inc., Ronald Williams, Appointed to Johnson & Johnson Board of Directors
Jun 6, 2011 DACOGEN® (decitabine) showed an overall survival advantage compared with the accepted standard therapies in older patients with newly diagnosed de novo or secondary acute myeloid leukemia
May 26, 2011 Johnson & Johnson Highlights Strategies for Growth Through Differentiated Medicines, Transformational Pipeline and Global Product Launches
May 25, 2011 New Four Year STELARA™* Data Show Consistent Safety Profile Over Time in Patients with Moderate to Severe Plaque Psoriasis
May 25, 2011 Interleukin-6 Inhibitor Sirukumab (CNTO 136) Phase 2 Data Show Promise in the Treatment of Active Rheumatoid Arthritis
May 23, 2011 Cilag GmbH International Announces Definitive Agreements to Acquire the Over-The-Counter Brands of J B Chemicals & Pharmaceuticals Limited
May 20, 2011 Cordis Receives FDA Approval for EXOSEAL™ Vascular Closure Device
May 20, 2011 FDA Approves EDURANT™ (Rilpivirine) for Use in Treatment-Naïve Adults with HIV-1
May 19, 2011 Johnson & Johnson to Host Pharmaceuticals Business Review
May 11, 2011 Janssen Identifies Trace Amounts of TBA in 5 Batches of PREZISTA®▼ (darunavir) in the EU and Canada
May 9, 2011 New Phase 3 Study Results Show REMICADE® is Effective in the Treatment of Pediatric Patients with Moderate to Severe Ulcerative Colitis
May 9, 2011 Phase 2b Data Show Treatment with Stelara® Induced and Maintained Clinical Response in Patients with Moderate to Severe Crohn's Disease
May 4, 2011 Johnson & Johnson to Participate in Bank of America Merrill Lynch 2011 Health Care Conference
Apr 28, 2011 Johnson & Johnson Holds 2011 Annual Meeting of Shareholders
Apr 28, 2011 Johnson & Johnson Announces Dividend Increase of 5.6%
Apr 28, 2011 ZYTIGA™ (Abiraterone Acetate) Receives FDA Approval for Treatment of Metastatic Prostate Cancer After Priority Review
Apr 27, 2011 Johnson & Johnson and Synthes Announce Definitive Merger Agreement to Create World's Most Innovative and Comprehensive Orthopaedics Business
Apr 26, 2011 Johnson & Johnson to Participate in Deutsche Bank 36th Annual Health Care Conference
Apr 20, 2011 Johnson & Johnson to Webcast Annual Meeting of Shareholders
Apr 19, 2011 Johnson & Johnson Reports 2011 First-Quarter Results
Apr 15, 2011 Johnson & Johnson Provides Additional Information Regarding Amended Agreement With Merck
Apr 15, 2011 Merck and Johnson & Johnson Reach Agreement on Distribution Rights for REMICADE® and SIMPONI®
Apr 14, 2011 Ortho-McNeil Neurologics Voluntarily Recalls Two Lots of TOPAMAX®
Apr 12, 2011 Johnson & Johnson to Host Analyst Conference Call on First-Quarter Results
Apr 11, 2011 INVEGA® Approved as Treatment for Schizophrenia in Adolescents
Apr 8, 2011 Johnson & Johnson Announces Settlement with U.S. Department of Justice and U.S. Securities and Exchange Commission
Apr 5, 2011 In Study of Acutely Ill Patients Rivaroxaban Compares Favorably With Enoxaparin in Preventing Venous Thromboembolism but With an Increased Rate of Bleeding
Mar 29, 2011 McNeil Consumer Healthcare Announces Voluntary Recall of Certain OTC Products
Mar 29, 2011 Tibotec Advances Global Clinical Research Program For TMC435 in HCV; Will Present Four Abstracts Evaluating Safety and Efficacy at EASL
Mar 21, 2011 Cordis Demonstrates Commitment to Advancing Therapies for Below-the-Knee Vascular Disease
Mar 14, 2011 Janssen Pharmaceutica NV Receives Offer to Acquire Its Animal Health Business
Mar 10, 2011 McNEIL-PPC, Inc. Announces Signing of Consent Decree Covering Manufacturing Facilities in Las Piedras, PR, Fort Washington, PA, and Lancaster, PA
Mar 9, 2011 European Commission Approves XEPLION® for Treatment of Schizophrenia
Mar 8, 2011 Johnson & Johnson Acquires 98.89% of Issued Crucell Shares as of the End of the Subsequent Offering Period and Crucell Intends to Delist Crucell Ordinary Shares and ADSs
Feb 23, 2011 Court of Appeals Overturns $1.8 Billion Patent Verdict for Centocor Ortho Biotech Inc.
Feb 23, 2011 Johnson & Johnson to Participate in 2011 RBC Capital Markets' Health Care Conference
Feb 22, 2011 Johnson & Johnson to Participate in 2011 Citi Global Health Care Conference
Feb 22, 2011 Johnson & Johnson Completes Tender Offer for Crucell and Declares Offer Unconditional
Feb 18, 2011 Tibotec Starts Global Phase 3 Clinical Trials Studying TMC435 In Adults With Chronic Genotype 1 HCV
Feb 17, 2011 Minimum Acceptance Condition Satisfied
Feb 14, 2011 Depuy Orthopaedics Receives FDA 510(K) Clearance for New Titanium Foam Implants
Feb 14, 2011 Depuy Orthopaedics Receives FDA 510(K) Clearance For Reclaim™ Revision Hip System
Feb 8, 2011 Crucell Shareholders Adopt Offer Governance Resolutions and Johnson & Johnson Makes Announcement on U.S. Regulatory Matters
Jan 28, 2011 Johnson & Johnson Receives Approval from European Commission
Jan 27, 2011 Tibotec Signs Multiple Agreements With Generic Manufacturers to Provide Access to New HIV Treatment
Jan 26, 2011 New Study Shows Tapentadol Extended Release (ER) May Significantly Reduce Average Pain Intensity for Diabetic Patients Suffering from Painful Peripheral Neuropathy
Jan 25, 2011 Johnson & Johnson Reports 2010 Fourth-Quarter and Full-Year Results
Jan 18, 2011 Johnson & Johnson to Host Analyst Meeting to Discuss Fourth-Quarter and Full-Year 2010 Financial Results
Jan 14, 2011 Johnson & Johnson Provides Update on McNeil Consumer Healthcare Remediation; Announces Completion of Internal Assessment Phase of Comprehensive Action Plan
Jan 14, 2011 McNeil Consumer Healthcare Initiates Voluntary Recall of Certain Over-The-Counter (OTC) Products
Jan 5, 2011 New Drug Application Submitted to FDA for Rivaroxaban for Prevention of Stroke in Patients with Atrial Fibrillation
Jan 4, 2011 INVEGA® Approved as First and Only Antipsychotic Treatment for Schizoaffective Disorder in the European Union
Jan 3, 2011 FDA Approves New Dosage Strength For Intelence®
Dec 29, 2010 Centocor Ortho Biotech Inc. Submits Application to FDA Seeking Remicad® Pediatric Ulcerative Colitis Indication
Dec 23, 2010 Janssen Inc. Announces New Drug Submission for Abiraterone Acetate for the Treatment of Metastatic Advanced Prostate Cancer
Dec 20, 2010 Centocor Ortho Biotech Inc. Announces NDA Submission for Abiraterone Acetate for the Treatment of Metastatic Advanced Prostate Cancer
Dec 17, 2010 Janssen Seeks European Marketing Authorization for Investigational Hepatitis C Treatment Telaprevir
Dec 15, 2010 Johnson & Johnson Announces Executive Appointments: Alex Gorsky, Vice Chairman, Executive Committee Sheri McCoy, Vice Chairman, Executive Committee
Dec 13, 2010 FDA Approves Prezista®/Ritonavir Once-Daily Dosing for HIV-1 Treatment-Experienced Adults With No Darunavir Resistance-Associated Mutations
Dec 9, 2010 Mcneil Consumer Healthcare Announces Voluntary Recall of All Lots of Rolaids® Extra Strength Softchews, Rolaids® Extra Strength Plus Gas Softchews, and Rolaids® Multi-Symptom Plus Anti-Gas Softchews Sold in the United States
Dec 8, 2010 Johnson & Johnson Launches Recommended Public Offer to Acquire Crucell
Dec 6, 2010 VELCADE® (bortezomib) in combination with rituximab improves progression- free survival, response rate and time to next anti-lymphoma treatment in patients with relapsed follicular lymphoma
Dec 6, 2010 VELCADE® (bortezomib) administered subcutaneously shows comparable response rates and safety profile compared to intravenous administration in the treatment of relapsed multiple myeloma
Dec 1, 2010 Janssen Pharmaceutica N.V. Announces Collaboration to Develop Diagnostic Biosignatures for Pre-Symptomatic Identification of Alzheimer's Disease
Nov 30, 2010 Johnson & Johnson and Crucell Progress Update: Expect to Commence Public Offer Prior to 10 December 2010
Nov 30, 2010 Cordis Enters Distribution Agreement with Ostial Solutions for the Worldwide Distribution of the OSTIAL PRO Stent Positioning System™
Nov 24, 2010 Johnson & Johnson to Participate in the Piper Jaffray 22nd Annual Health Care Conference
Nov 19, 2010 Analysis of Longer-Term Clinical Study Suggests Psychiatric Hospitalization Rates Decreased in Adults with Schizophrenia Treated with INVEGA® SUSTENNA®
Nov 18, 2010 Ethicon Submits Biologic License Application to the FDA for the Fibrin Pad
Nov 17, 2010 Patients with Common Heart Rhythm Disorder Demonstrated Improvements in Symptoms and Quality of Life with Catheter Ablation Compared to Treatment with Drug Therapy
Nov 15, 2010 Mcneil Consumer Healthcare Announces Voluntary Recall of All Lots of Rolaids(R) Extra Strength Softchews, Rolaids(R) Extra Strength Plus Gas Softchews, and Rolaids(R) Multi-Symptom Plus Anti-Gas Softchews Sold In the United States
Nov 14, 2010 Scios Announces Results of ASCEND Heart Failure Study at the Scientific Sessions of the American Heart Association
Nov 11, 2010 Centocor Ortho Biotech Inc. Submits Application to FDA Seeking to Expand SIMPONI® Label to Include Inhibition of Structural Damage in Treatment of Psoriatic Arthritis
Nov 11, 2010 SEDASYS® System Appeal Has Been Granted By The FDA
Nov 8, 2010 New Magnetic Resonance Imaging (MRI) Data Show Efficacy of SIMPONI® in Treatment of Rheumatoid Arthritis
Nov 4, 2010 Johnson & Johnson to Participate in Credit Suisse 19th Annual Health Care Conference
Nov 4, 2010 Ethicon Endo-Surgery Urges FDA to Grant SEDASYS® System Appeal
Nov 3, 2010 virco®TYPE HIV-1 resistance test achieves CE- Marking approval
Nov 2, 2010 Ortho-McNeil-Janssen Pharmaceuticals, Inc. Enters into Agreement for CONCERTA(R) Authorized Generic
Nov 1, 2010 Ortho Clinical Diagnostics Receives FDA Clearance for Intact Parathyroid Hormone Assay
Nov 1, 2010 Week 24 Interim Results From Phase 2b PILLAR Study to be Presented as Late-breaker at AASLD
Oct 29, 2010 Johnson & Johnson and Crucell Provide Progress Update on Preparations for Public Offer
Oct 29, 2010 New Data Analyses on CONCERTA® Pediatric Treatment Include Insight on Handwriting Performance and Attention in ADHD
Oct 19, 2010 Johnson & Johnson Reports 2010 Third-Quarter Results:
Oct 18, 2010 McNeil Consumer Healthcare Announces Voluntary Recall of One Product Lot of Tylenol® 8 Hour Caplets 50 Count Sold in the United States and Puerto Rico
Oct 11, 2010 Johnson & Johnson to Host Analyst Meeting to Discuss Third-Quarter Financial Results and Review Pharmaceutical Business
Oct 11, 2010 Abiraterone Acetate Significantly Improved Overall Survival for Patients with Metastatic Advanced Prostate Cancer
Oct 6, 2010 Johnson & Johnson and Crucell Reach Agreement on Intended Public Offer of Euro 24.75 per Ordinary Share of Crucell
Oct 4, 2010 FDA Issues Complete Response Letter to Johnson & Johnson Pharmaceutical Research & Development Regarding New Drug Application for Tapentadol Extended Release
Oct 4, 2010 Ethicon, Inc. Introduces Two Innovative Devices for Minimally Invasive Hernia Repair during American College of Surgeons (ACS) Annual Meeting
Sep 30, 2010 Janssen to Assume CAEYLX® Global Marketing Rights from Merck
Sep 27, 2010 Johnson & Johnson Completes Acquisition of Micrus Endovascular
Sep 27, 2010 CYPHER(R) Sirolimus Drug-Eluting Stent Remains Unsurpassed in Terms of Safety and Efficacy
Sep 27, 2010 Acclarent, Inc. Introduces Two New Innovations for Minimally-Invasive Sinus Surgery during AAO - Head and Neck Surgery Conference
Sep 27, 2010 Centocor Ortho Biotech Inc. Submits Application to FDA Seeking to Expand Simponi® Label in Treatment of Rheumatoid Arthritis
Sep 27, 2010 Phase 3 Study Compares Tapentadol Extended Release Tablets to Placebo in Patients with Chronic Low Back Pain
Sep 22, 2010 Economic Model Presented at TCT 2010 Suggests That the Use of CYPHER Drug Eluting Stent May Result in Substantial Cost Savings When Compared to Other Drug Eluting Stents
Sep 20, 2010 Data from Landmark Study Evaluating Gender Differences In Response To An HIV Therapy Published In Annals Of Internal Medicine
Sep 17, 2010 Johnson & Johnson and Crucell In Advanced Negotiations for an All Cash Public Offer of Euro 24.75 Per Ordinary Share of Crucell
Sep 16, 2010 Colleen Goggins, Worldwide Chairman, Consumer Group Plans Retirement From Johnson & Johnson in Early 2011
Sep 9, 2010 Study of Investigational Agent Abiraterone Acetate for Metastatic Advanced Prostate Cancer Unblinded After Meeting Pre-Determined Criteria
Sep 3, 2010 Tibotec Pharmaceuticals Seeks European Marketing Authorization for Investigational Once-Daily HIV Treatment TMC278
Sep 2, 2010 Long Term Data Presented at ESC 2010 Shed Further Light on the Benefit of the CYPHER(R) Sirolimus Drug-Eluting Stent Compared to the ENDEAVOR(R) Zotarolimus-Eluting Stent in Important High-Risk Subgroups
Aug 31, 2010 Rivaroxaban Successfully Demonstrated Non-Inferiority Compared to Standard of Care for the Prevention of Recurrent Venous Thromboembolism in Pivotal Phase 3 Study
Aug 31, 2010 CORDIS announces results of ten-year CYPHER® Sirolimus-eluting coronary stent follow-up
Aug 30, 2010 Pivotal Phase 3 Study Compares Tapentadol Extended Release Tablets to Placebo in Patients with Chronic Osteoarthritis Knee Pain
Aug 26, 2010 DePuy Orthopaedics Voluntarily Recalls ASR(TM) Hip System
Aug 9, 2010 STELARA®Three-Year Efficacy and Safety Data Presented on Patients with Moderate to Severe Plaque Psoriasis
Jul 26, 2010 Tibotec Pharmaceuticals Submits New Drug Application for Investigational Once-Daily HIV Treatment TMC278 to U.S. Food and Drug Administration
Jul 22, 2010 TMC278 Pivotal Phase 3 Clinical Trials Achieve Primary Objective
Jul 20, 2010 Johnson & Johnson Reports 2010 Second-Quarter Results:
Jul 19, 2010 Former McKinsey & Company Chairman and Managing Director Ian Davis Appointed to Johnson & Johnson Board of Directors
Jul 19, 2010 Phase 3 Open-Label Study Comparing Tapentadol Extended Release Tablets to Oxycodone Controlled Release Tablets Published by Pain Practice
Jul 13, 2010 Johnson & Johnson to Host Analyst Conference Call on Second-Quarter Results
Jul 12, 2010 Johnson & Johnson Announces Definitive Agreement to Acquire Micrus Endovascular
Jul 12, 2010 Ethicon Endo-Surgery Completes Divestiture of Breast Care Business to Devicor Medical Products
Jul 8, 2010 McNeil Consumer Healthcare Announces Voluntary Recall of Certain Over-The-Counter (OTC) Products in the United States, Fiji, Guatemala, Dominican Republic, Puerto Rico, Trinidad & Tobago, and Jamaica
Jun 28, 2010 Ortho-McNeil-Janssen Pharmaceuticals, Inc. Announces Oncology Research Collaboration Agreement with the Koch Institute for Integrative Cancer Research at MIT
Jun 26, 2010 Johnson & Johnson Pharmaceutical Research & Development Reports Phase 2b Clinical Trial Results Evaluating Canagliflozin to Treat Type 2 Diabetes
Jun 24, 2010 McNeil Consumer Healthcare
Jun 23, 2010 Biosense Webster Receives FDA Clearances for the CARTOXPRESS(TM) Software Module and LASSO(R) NAV Catheter for its CARTO(R) XP System
Jun 22, 2010 Ortho-McNeil-Janssen Pharmaceuticals, Inc. Enters Agreement to Develop and Commercialize Antigen-Based Therapy for Type 1 Diabetes
Jun 21, 2010 Ethicon Endo-Surgery Introduces HARMONIC ACE®45 cm Curved Shears At ASMBS
Jun 17, 2010 VISTAKON(R) Launches 1-DAY ACUVUE(R) TruEye(TM) Brand Contact Lenses
Jun 16, 2010 EMEA Approves Update to Velcade® (bortezomib) Label to Include Survival Benefit in Previously Untreated Patients with Multiple Myeloma
Jun 15, 2010 McNeil Consumer Healthcare Recalls Four Product Lots Of Benadryl® Allergy Ultratab™ Tablets, 100 Count, and One Product Lot of Extra Strength Tylenol® Rapid Release Gels, 50 Count
Jun 7, 2010 Janssen Pharmaceutica N.V. Announces Expansion of Licensing Agreement for Tapentadol (NUCYNTA® /PALEXIA® /PALEXIS®)
Jun 3, 2010 Johnson & Johnson Highlights Growth Strategies for its World-Leading Medical Devices & Diagnostics Segment
Jun 1, 2010 Centocor Ortho Biotech Inc. Acquires RespiVert LTD., Strengthens Pulmonary Focus
May 25, 2010 Johnson & Johnson to Host Medical Devices & Diagnostics Business Review
May 25, 2010 NEVO(TM) Sirolimus-eluting Coronary Stent Continues to Demonstrate Excellent Safety and Efficacy Outcomes in New Twelve-Month Data
May 24, 2010 New Data on Invega® Sustenna® and Risperdal® Consta® For Schizophrenia
May 20, 2010 Johnson & Johnson to Participate in 2010 Citi Investment Research Global Health Care Conference
May 20, 2010 Depuy Mitek To Launch Bristow-Latarjet Instability Shoulder System For Treatment Of Recurrent Joint Instability
May 13, 2010 Biosense Webster Introduces the THERMOCOOL® SF Irrigated Catheter in the European Union
May 11, 2010 Ethicon Endo-Surgery Introduces Harmonic Focus® Long Curved Shears For Deep Surgical Access
May 7, 2010 Data Comparing Nucynta® (Tapentadol) Tablets To Oxycodone Immediate Release Tablets Presented At 2010 American Pain Society Annual Meeting
May 4, 2010 McNeil Consumer Healthcare Statement Regarding FDA Inspection Report
May 4, 2010 Johnson & Johnson to Participate in Bank of America Merrill Lynch 2010 Health Care Conference
May 3, 2010 Ethicon Endo-Surgery SEDASYS® System Receives Regulatory Approval in Canada and CE Mark in European Union
May 3, 2010 TAPENTADOL DATA TO BE PRESENTED AT 2010 AMERICAN PAIN SOCIETY ANNUAL MEETING
Apr 30, 2010 McNeil Consumer Healthcare Announces Voluntary Recall of Certain OTC Infants' and Children's Products
Apr 29, 2010 Ortho-McNeil-Janssen Pharmaceuticals, Inc. Resolves Investigation of Past TOPAMAX® Marketing and Promotional Activities
Apr 27, 2010 Johnson & Johnson to Participate in Deutsche Bank 35th Annual Health Care Conference
Apr 27, 2010 ASP Sterrad Technology Approved By AFSSAPS for Total Inactivation of Prions
Apr 26, 2010 CONCERTA(R) Patent Appeal Denied
Apr 22, 2010 Johnson & Johnson Announces Dividend Increase of 10.2%
Apr 20, 2010 Johnson & Johnson Reports 2010 First-Quarter Results:
Apr 15, 2010 Johnson & Johnson to Webcast Annual Meeting of Shareholders
Apr 15, 2010 Remicade® Study Results Show Greater Steroid-Free Remission and Mucosal Healing Compared With Conventional Immunomodulator Azathioprine in Treatment of Crohn's Disease
Apr 14, 2010 New Study on Continuity of Care for Patients with Schizophrenia and Schizoaffective Disorder Presented at 2010 Quality of Behavioral Health Care Conference
Apr 13, 2010 FDA Approves New Drug Application for PANCREAZE(TM)
Apr 13, 2010 Johnson & Johnson to Host Analyst Conference Call on First-Quarter Results
Apr 9, 2010 First Patients Enrolled in Cordis Trial of New Stent Graft System to Treat Abdominal Aortic Aneurysm
Mar 30, 2010 Ethicon Endo-Surgery Announces Receipt of Offer to Purchase Breast Care Business
Mar 15, 2010 Positive Long Term Data Presented At ACC 2010 Demonstrate Sustained Safety and Efficacy Advantages of the Cypher® Sirolimus Drug-Eluting Stent Over the Endeavor® Zotarolimus-Eluting Stent
Mar 11, 2010 Cordis Unveils Next Generation CoCr Coronary Stent
Mar 5, 2010 Johnson & Johnson Consumer Companies, Inc., Unveils CYTOMIMIC(TM) Technology at 68th Annual Meeting of the American Academy of Dermatology
Mar 4, 2010 STELARATM and REMICADE® Data in Treatment of Plaque Psoriasis to be Presented at American Academy of Dermatology (AAD) Meeting
Mar 2, 2010 Johnson & Johnson to Participate in the 30th Annual Cowen and Company Health Care Conference
Feb 24, 2010 New Guidelines Recommend DORIBAX® For Initial Treatment Of Complicated Intra-Abdominal Infections In Adults
Feb 24, 2010 LifeScan Recalls Specific Lots of Consumer and Professional OneTouch® SureStep® Test Strips Due To Inaccurate Readings at High Levels
Feb 23, 2010 Johnson & Johnson to Participate in RBC Capital Markets' Health Care Conference
Feb 19, 2010 Ethicon Endo-Surgery Announces Agreement with Hologic Inc. To Resolve Patent Disputes
Feb 19, 2010 CHMP adopts negative opinion for ZEFTERA™
Feb 17, 2010 New Study Compares Efficacy And Safety Of Once-Daily Versus Twice-Daily Prezista® Regimen In Treatment-Experienced Adult Patients With No Prezista Mutations
Feb 16, 2010 Centocor Ortho Biotech Products and Amgen Finalize ESA Risk Evaluation and Mitigation Strategy (Rems) with FDA
Feb 9, 2010 PREZISTA®* Now Approved as Part of Combination Therapy for Pediatric Patients Six Years of Age and Older with HIV
Feb 4, 2010 Tapentadol Extended Release Data To Be Presented At American Academy Of Pain Medicine Annual Meeting
Feb 1, 2010 Cordis Corporation Announces Agreement With Boston Scientific To Resolve Certain Coronary Stent Patent Disputes
Jan 27, 2010 U.S. Food and Drug Administration Approves Labeling Update for PREZISTA® To Include 96-Week Data in HIV-1 Infected Adult Patients
Jan 26, 2010 Johnson & Johnson Reports 2009 Fourth-Quarter and Full-Year Results:
Jan 20, 2010 Ethicon Completes Acquisition of Acclarent
Jan 19, 2010 Johnson & Johnson to Host Analyst Meeting to Discuss Fourth-Quarter and Full-Year 2009 Financial Results
Jan 15, 2010 McNeil Consumer Healthcare Announces Voluntary Recall of Certain Over-the-Counter (OTC) Products in the Americas, UAE, and Fiji
Jan 14, 2010 Stelara®* Shows Greater Efficacy than Etanercept for Treatment of Moderate-to-Severe Plaque Psoriasis
Dec 30, 2009 FDA Issues Complete Response Letter for Ceftobiprole
Dec 16, 2009 Ethicon Announces Definitive Agreement to Acquire Acclarent
Dec 10, 2009 Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection
Dec 6, 2009 Phase III Study of Rivaroxaban Shows That Extending Anticoagulant Treatment by Six or 12 Months Significantly Reduced Risk of Second Symptomatic VTE
Dec 4, 2009 Janssen-Cilag Submits Marketing Authorisation Application in Europe for Paliperidone Palmitate for the Treatment of Schizophrenia
Dec 1, 2009 New Drug Application Submitted to FDA for Tapentadol Extended Release Tablets for Management of Chronic Pain
Nov 25, 2009 U.S. Food and Drug Administration (FDA) Grants Traditional Approval for INTELENCE® (ETRAVIRINE)
Nov 23, 2009 ASP Announces Acquisition of Gloster Europe to Help Reduce Infections in Healthcare Facilities
Nov 5, 2009 Johnson & Johnson to Participate in Credit Suisse 18th Annual Health Care Conference
Nov 3, 2009 Johnson & Johnson Announces Restructuring Initiatives for Sustainable Growth
Oct 22, 2009 Xerox Chairman Anne M. Mulcahy Appointed to Johnson & Johnson Board of Directors
Oct 19, 2009 New SIMPONI(TM) Data Show Long-Term Efficacy in Treatment of Rheumatoid Arthritis
Oct 19, 2009 New SIMPONI(TM) Data Show Inhibition of Joint Damage in Patients With Rheumatoid Arthritis and Psoriatic Arthritis
Oct 15, 2009 Biosense Webster Receives FDA Clearance for the CARTO(R) 3 System
Oct 14, 2009 Ortho Clinical Diagnostics Receives FDA Approval for First Anti-HIV 1+2 Test for Use on Random Access, Integrated Laboratory Testing System
Oct 13, 2009 Johnson & Johnson Reports 2009 Third-Quarter Results:
Oct 6, 2009 Johnson & Johnson to Host Analyst Meeting to Discuss Third-Quarter Financial Results and Review Medical Devices & Diagnostics Business
Oct 6, 2009 Simponi™ (Golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis With Novel Smartject™ Autoinjector
Sep 29, 2009 Cordis Corporation Announces Agreement with Boston Scientific to Settle Selected Stent Litigation Cases
Sep 28, 2009 Johnson & Johnson and Crucell Announce Strategic Collaboration to Develop Innovative Products, Including Therapies for Influenza Prevention and Treatment
Sep 25, 2009 STELARA ™ (ustekinumab) Receives FDA Approval For Treatment Of Moderate To Severe Plaque Psoriasis With Four-Times-A-Year Maintenance Dosing
Sep 24, 2009 NEVO(TM) Sirolimus-Eluting Coronary Stent Associated with Significantly Less Chest Pain at Six Months Than Taxus(R) Liberte(R) Stent
Sep 23, 2009 Janssen-Cilag's STELARA®▼ (ustekinumab) Approved by NICE for the Treatment of Moderate to Severe Plaque Psoriasis
Sep 21, 2009 2.25 MM CYPHER(R) Sirolimus-eluting Coronary Stent Approved by FDA
Sep 17, 2009 Johnson & Johnson and Elan Corporation plc Announce Closing of Transaction Related to Alzheimer's Immunotherapy Program and Equity Investment
Sep 10, 2009 Centocor Ortho Biotech Receives FDA Complete Response Letter Regarding Doxil( R) for the Treatment of Advanced Breast Cancer
Sep 10, 2009 FDA Issues Complete Response Letter for Trabectedin Combined with DOXIL
Sep 8, 2009 Johnson & Johnson to Participate in Morgan Stanley Global Healthcare Unplugged Conference
Aug 31, 2009 First Patient Enrolled in CYPRESS, a Dual Antiplatelet Therapy Trial with the CYPHER(R) Sirolimus-Eluting Coronary Stent
Aug 21, 2009 FDA Issues Complete Response Letter for Carisbamate
Aug 19, 2009 DePuy receives FDA Advisory Panel Recommendation for Pinnacle( R) CoMplete( TM) Acetabular Hip System
Aug 3, 2009 Video: FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia
Jul 31, 2009 FDA Approves INVEGA( R) SUSTENNA( TM) for the Acute and Maintenance Treatment of Schizophrenia
Jul 31, 2009 INVEGA( R) Approved as the First and Only Treatment for Schizoaffective Disorder
Jul 21, 2009 FDA Approves Vitros( R) Anti-HCV Assay For Use On Vitros 5600( R) Integrated And Vitros 3600( R) Immunodiagnostic Systems
Jul 21, 2009 Ortho Clinical Diagnostics Launches 24-Hour Remote Monitoring Center
Jul 20, 2009 New HIV Study Shows That Large Numbers of Women and People of Color can be Successfully Enrolled in U.S. HIV Clinical Studies
Jul 20, 2009 96-Week Safety and Efficacy Findings Presented for Intelencetm (Etravirine) as Part of HIV Combination Therapy
Jul 16, 2009 Tibotec Pharmaceuticals Announces Agreement to Develop and Commercialize a New Fixed-Dose Combination of TMC278 and Truvada® with Gilead Sciences
Jul 15, 2009 Centocor Ortho Biotech Statement on FDA ODAC Opinion Regarding Doxil( R) for Treatment of Advanced Breast Cancer
Jul 15, 2009 Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding Trabectedin for Relapsed Ovarian Cancer
Jul 14, 2009 Johnson & Johnson Reports 2009 Second-Quarter Results:
Jul 10, 2009 Johnson & Johnson Completes Acquisition of Cougar Biotechnology
Jul 7, 2009 Johnson & Johnson to Host Analyst Conference Call on Second-Quarter Results
Jul 3, 2009 Johnson & Johnson Completes Initial Tender Offer for Cougar Biotechnology
Jul 2, 2009 Johnson & Johnson and Elan Corporation plc Announce Definitive Agreement for Alzheimer's Immunotherapy Program and Equity Investment
Jun 29, 2009 Centocor Ortho Biotech Inc. Awarded $1.67 Billion Patent Jury Verdict from Abbott Laboratories
Jun 26, 2009 Simponi™ (Golimumab) Receives Positive Opinion From CHMP For Once-Monthly Subcutaneous Treatment Of Rheumatoid Arthritis, Psoriatic Arthritis And Ankylosing Spondylitis
Jun 23, 2009 NUCYNTATM™(tapentadol) CII Immediate Release Tablets Now Available for Relief of Moderate to Severe Acute Pain
Jun 17, 2009 Johnson & Johnson Announces Regulatory Clearance for Its Planned Acquisition of Cougar Biotechnology
Jun 17, 2009 Unique Collaboration Between TB Alliance and Tibotec to Accelerate Tuberculosis Drug Development
Jun 12, 2009 Biosense Webster to Support Landmark Clinical Trial of Atrial Fibrillation
Jun 9, 2009 New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients
Jun 9, 2009 Two-Year Data Show Patients Receiving SIMPONI(TM) (golimumab) Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis and Ankylosing Spondylitis
Jun 5, 2009 Johnson & Johnson Begins Tender Offer to Acquire Cougar Biotechnology
Jun 4, 2009 Johnson & Johnson Highlights Pharmaceutical Growth Strategies and Robust Pipeline to Address Unmet Medical Needs
Jun 3, 2009 Data on Investigational Drug TMC207 for Treatment of MDR-Tuberculosis, Published in New England Journal of Medicine
Jun 2, 2009 New One-Year Data from REMICADE(R) SONIC Trial Show Sustained Efficacy Compared with Azathioprine in Treatment of Crohn's Disease
May 28, 2009 FDA Advisory Panel Recommends Approval of the SEDASYS® System
May 28, 2009 Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting
May 28, 2009 FDA Issues Complete Response Letter for Rivaroxaban
May 27, 2009 Johnson & Johnson Files Arbitration Demand Against Schering-Plough to Resolve Dispute Over Agreements for REMICADE(R) and SIMPONI(TM)
May 27, 2009 Johnson & Johnson to Host Pharmaceutical Business Review
May 26, 2009 FDA Extends Review Timeline for STELARA(TM) (ustekinumab) Biologic License Application by Three Months
May 26, 2009 New Phase 3 Study of Tapentadol Immediate Release Tablets Published in Current Medical Research and Opinion Journal
May 21, 2009 Johnson & Johnson Announces Definitive Agreement to Acquire Cougar Biotechnology, Inc.
May 19, 2009 RISPERDAL® CONSTA® (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder
May 19, 2009 New Data Demonstrate RISPERDAL® CONSTA® (Risperidone) Long-Acting Treatment May Improve Health Outcomes and Reduce Hospitalizations in Patients with Schizophrenia
May 19, 2009 In Patients with Heart Attacks, CYPHER(R) Sirolimus-Eluting Coronary Stent Results Sustained out to Four Years Compared to Bare Metal Stents
May 19, 2009 NEVO(TM) Sirolimus-Eluting Coronary Stent Yields Superior Results to Taxus(R) Liberte(R) Stent in Pivotal Clinical Trial
May 18, 2009 FDA Grants Approval for Use of RISPERDAL® CONSTA® as Both a Monotherapy and Adjunctive Therapy in the Maintenance Treatment of Bipolar I Disorder
May 14, 2009 Benefits of Catheter Ablation with the NAVISTAR(R) THERMOCOOL(R) Catheter Sustained for One Year in the Treatment of Symptomatic, Paroxysmal Atrial Fibrillation
May 13, 2009 Retrospective Analysis Finds Treatment of Cancer Chemotherapy Patients with Epoetin Alfa Associated with Lower Drug Cost than Darbepoetin Alfa
May 13, 2009 Biosense Webster to Showcase Advanced Ablation Technologies for Electrophysiologists at HRS 2009
May 13, 2009 Johnson & Johnson to Participate in Deutsche Bank 34th Annual Health Care Conference
May 12, 2009 Johnson & Johnson to Host Analyst Conference Call To Review Six-Month Trial Results From NEVO RES I
May 7, 2009 Johnson & Johnson Announces Support for Kohl-Grassley Physician Payments Sunshine Act of 2009
May 7, 2009 Cellsearch® System to be Offered at Florida Cancer Specialists
May 7, 2009 Three Clinical Presentations on Tapentadol Extended Release Tablets for Chronic Pain Featured at 2009 American Pain Society Annual Meeting
May 5, 2009 Johnson & Johnson to Participate in Bank of America and Merrill Lynch 2009 Health Care Conference
Apr 24, 2009 Simponi™ (Golimumab) Receives FDA Approval As First Once-Monthly Anti-TNF For Treatment Of Rheumatoid Arthritis, Psoriatic Arthritis
Apr 23, 2009 Johnson & Johnson Announces Dividend Increase of 6.5%
Apr 22, 2009 Ethicon Endo-Surgery Novel Investigational Notes and SSL Devices Featured In 15 Presentations At SAGES
Apr 22, 2009 FDA Grants Ethicon Endo-Surgery Approval of its IDE Application to Commence Study of Notes Toolbox™
Apr 21, 2009 Virco Lab, Inc. enters into Collaboration with SmartGene, Inc. enhancing HIV resistance test services for laboratories and physicians
Apr 16, 2009 Johnson & Johnson to Webcast Annual Meeting of Shareholders
Apr 14, 2009 Johnson & Johnson Reports 2009 First-Quarter Results
Apr 13, 2009 Health Canada Approves Simponi™ (Golimumab) For Treatment Of Rheumatoid Arthritis, Psoriatic Arthritis And Ankylosing Spondylitis
Apr 9, 2009 New Clinical Data at ACC09 Show the CYPHER(R) Sirolimus-eluting Coronary Stent Outperformed TAXUS(R) LIBERTE(R) and ENDEAVOR(R) Stents in Key Outcome Measures
Apr 7, 2009 Health Canada Approves PREZISTA* Once Daily as Part of Combination Therapy for Treatment-Naive Adults with HIV-1
Apr 7, 2009 Johnson & Johnson to Host Analyst Conference Call on First-Quarter Results
Apr 1, 2009 Study Suggests Treatment with Paliperidone ER Significantly Improves Symptoms of Schizoaffective Disorder
Mar 31, 2009 District Court Decision Received in CONCERTA® Patent Case
Mar 23, 2009 U.S. FDA Approves New THERAKOS™ CELLEX™ Photopheresis System
Mar 19, 2009 FDA Advisory Committee Finds Favorable Risk-Benefit Profile for Oral Anticoagulant Rivaroxaban for Prophylaxis of Deep Vein Thrombosis and Pulmonary Embolism after Hip or Knee Replacement Surgery
Mar 16, 2009 Cordis Corporation Announces Head-to-Head Randomized Clinical Trial Comparing the NEVO(TM) Sirolimus-Eluting Coronary Stent to the XIENCE(TM) Stent
Mar 12, 2009 Johnson & Johnson to Provide Webcast Presentation of Tapentadol Extended Release (ER) Phase 3 Clinical Data Presented at World Institute of Pain 5th Annual World Congress
Mar 10, 2009 Johnson & Johnson to Participate in the 29th Annual Cowen & Company Health Care Conference
Mar 5, 2009 CYPHER(R) Sirolimus-eluting Coronary Stent Demonstrates Sustained Benefits Compared to Bare-Metal Stents in Six-Year Randomized Clinical Trial
Feb 24, 2009 CHMP delays European Commission decision process to approve ZEVTERA ™
Feb 10, 2009 FDA Issues Complete Response Letter for RISPERDAL(R) CONSTA(R) for the Adjunctive Maintenance Treatment of Bipolar Disorder
Feb 10, 2009 Priligy™ (Dapoxetine) Receives First Regulatory Approvals for the Treatment of Premature Ejaculation (PE) in Finland and Sweden
Feb 6, 2009 FDA Grants Marketing Approval to NAVISTAR(R) THERMOCOOL(R) Catheter for Atrial Fibrillation
Feb 6, 2009 Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Announces FDA Filings for Paliperidone Palmitate and INVEGA(R)
Feb 5, 2009 Tibotec Submits Application to U.S. Food and Drug Administration Seeking Traditional Approval for INTELENCE™ (etravirine)
Feb 3, 2009 Once-Daily Prezista® (darunavir) for Treatment-Naïve Adults with HIV-1 Receives Approval in the European Union as Part of Combination Therapy
Jan 28, 2009 Health Canada Clears New Therakos™ Cellex™ Photopheresis System
Jan 23, 2009 Johnson & Johnson Completes Acquisition of Mentor Corporation
Jan 23, 2009 Johnson & Johnson Completes Tender Offer for Mentor Corporation
Jan 22, 2009 NEW BIOLOGIC STELARA™ RECEIVES APPROVAL IN EUROPE FOR TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS
Jan 20, 2009 Johnson & Johnson Reports Full-Year and Fourth-Quarter 2008 Results
Jan 17, 2009 Johnson & Johnson Completes Initial Tender Offer for Mentor Corporation with 92.9% of Shares Tendered
Jan 15, 2009 Johnson & Johnson Announces Satisfaction of Regulatory Clearances Condition for its Proposed Acquisition of Mentor Corporation
Jan 15, 2009 Court of Appeals Overturns 2005 Patent Verdict Against Cordis
Jan 13, 2009 Johnson & Johnson to Review Fourth-Quarter and Full-Year 2008 Financial Results
Jan 6, 2009 Johnson & Johnson Extends Tender Offer for Mentor Corporation
Dec 30, 2008 Johnson & Johnson Completes Acquisition of Omrix Biopharmaceuticals, Inc.
Dec 27, 2008 Johnson & Johnson Completes Tender Offer for Omrix Biopharmaceuticals, Inc.
Dec 23, 2008 VITROS® 3600 Immunodiagnostic System for Laboratory Diagnostics Receives 510(K) Clearance from the FDA
Dec 19, 2008 Johnson & Johnson Extends Tender Offer for Omrix Biopharmaceuticals, Inc.
Dec 19, 2008 Johnson & Johnson Strengthens Wellness & Prevention Platform with Acquisition of Human Performance Institute(TM)
Dec 19, 2008 FDA Issues Complete Response Letter to Centocor for Ustekinumab Biologic License Application
Dec 16, 2008 ETHICON Launches the Latest Innovation in Hernia Repair Platform
Dec 15, 2008 Approval of STELARATM in Canada Marks Advancement in Treatment of Moderate to Severe Plaque Psoriasis
Dec 14, 2008 Study Finds DOXIL® Combination Therapy Delays Disease Progression for Patients with Metastatic Breast Cancer
Dec 12, 2008 Johnson & Johnson Begins Tender Offer to Acquire Mentor Corporation
Dec 11, 2008 Johnson & Johnson Announces Receipt of Israeli Antitrust Approval for Acquisition of Omrix
Dec 9, 2008 Phase 3 Data Demonstrate Efficacy and Tolerability of Paliperidone Palmitate, an Investigational Long-Acting Therapy for the Treatment of Schizophrenia
Dec 9, 2008 Velcade® (Bortezomib) Findings Reinforce Efficacy And Survival Across Multiple Patient Populations
Dec 7, 2008 Rivaroxaban Reduces Symptomatic VTE & Death Following Knee or Hip Replacement Surgery by More Than 50% Compared to Enoxaparin in Pooled Analysis of the RECORD Clinical Trial Program
Dec 6, 2008 Phase III Data Demonstrates Efficacy and Tolerability of Carisbamate as an Adjunctive Therapy for Partial Onset Seizures
Dec 6, 2008 Observational Study Finds Changes in Medicare Reimbursement for Erythropoiesis-stimulating Agents Associated with Increased Need for Blood Transfusion
Dec 3, 2008 Tibotec and Emcure Collaborate on Access to Darunavir for India
Dec 3, 2008 Prezista® (Darunavir) Receives Expanded Marketing Authorisation In The European Union For Treatment-Experienced Adults With HIV-1
Dec 1, 2008 ETHICON Completes Divestiture of Professional Wound Care Business to One Equity Partners
Dec 1, 2008 Johnson & Johnson Announces Definitive Agreement to Acquire Mentor Corporation
Nov 27, 2008 European Committee for Human Medicinal Products (CHMP) Issues Positive Opinion For Once-Daily PREZISTA® (darunavir) as Part of Combination Therapy for Treatment-Naïve Adults With HIV-1
Nov 26, 2008 FDA Issues Complete Response Letter for Ceftobiprole for Treatment of Complicated Skin Infections
Nov 25, 2008 Johnson & Johnson Begins Tender Offer to Acquire Omrix
Nov 24, 2008 Johnson & Johnson Announces Definitive Agreement to Acquire Omrix
Nov 21, 2008 New Antibiotic Against Serious Infections
Nov 21, 2008 FDA Approves Tapentadol Immediate-Release Tablets for Relief of Moderate to Severe Acute Pain
Nov 20, 2008 European Agency for the Evaluation of Medicinal Products Recommends Suspension of Marketing Authorisation for IONSYS®
Nov 20, 2008 FDA Advisory Panel Unanimously Recommends Approval of NAVISTAR® THERMOCOOL® Catheter for Atrial Fibrillation
Nov 20, 2008 Tibotec Begins Enrollment in Europe for Phase III Trial of Telaprevir in HCV Patients who Failed Prior Treatment
Nov 20, 2008 Tibotec Presents Interim Findings for TMC435, an Investigational Genotype 1 Hepatitis C Treatment, at the AASLD Liver Meeting 2008
Nov 20, 2008 Ortho Biotech Announces NDA Submission for Trabectedin for the Treatment of Relapsed Ovarian Cancer
Nov 18, 2008 Long-Term Titan Study Evaluates Prezista®/Ritonavir vs. Lopinavir/Ritonavir as Part of HIV Combination Therapy in Treatment-Experienced Adults
Nov 18, 2008 Magnetically Steered Irrigated Tip Cardiac Catheter for Treatment of Irregular Heart Rhythms Now Available Throughout the European Union
Nov 13, 2008 New Antibiotic Against Serious Infections - Receives First Approval in Europe
Nov 12, 2008 Tibotec Data Presented at ICAAC and HIV9 Follow key Regulatory Approvals for Anti-HIV Compounds
Nov 11, 2008 Study Finds Catheter Ablation with the NAVISTAR(R) THERMOCOOL(R) Catheter Superior to Anti-Arrhythmic Drug Therapy for the Treatment of Symptomatic, Paroxysmal Atrial Fibrillation
Nov 10, 2008 Johnson & Johnson-Merck Consumer Pharmaceuticals Company Announces Urgent Voluntary Nationwide Recall of Infants' MYLICON(R) GAS RELIEF DYE FREE Drops (Simethicone-Antigas) Non-Staining Due to Possible Metal Fragments
Nov 6, 2008 Johnson & Johnson to Participate in Credit Suisse 2008 Health Care Conference
Nov 1, 2008 Study Suggests Treatment with Paliperidone ER Significantly Improves Symptoms of Schizoaffective Disorder
Oct 30, 2008 TCT2008 Concludes with Presentation of Positive Data for the CYPHER(R) Sirolimus-eluting Coronary Stent
Oct 27, 2008 Johnson & Johnson Establishes Wellness & Prevention Platform with Acquisition of HealthMedia, Inc.
Oct 27, 2008 New Data Show In Vitro Potency of Doripenem Against Resistant Bacteria
Oct 27, 2008 Golimumab Phase 3 Data Show Significant Improvement in Physical Function in Patients with Rheumatoid Arthritis
Oct 27, 2008 Patient Enrollment Complete for Pivotal Trial of the NEVO(TM) Sirolimus-eluting Coronary Stent with Unique Reservoir Technology
Oct 27, 2008 One-Year Data Show Golimumab Improved Signs and Symptoms in Patients with Psoriatic Arthritis in Phase 3 Study
Oct 24, 2008 FDA Clears VITROS® 5600 Integrated System for Laboratory Diagnostics
Oct 24, 2008 Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Submits New Drug Application to FDA for Carisbamate
Oct 22, 2008 U.S. Food and Drug Administration (FDA) Approves PREZISTA® Once-Daily as Part of Combination Therapy for Treatment-Naïve Adults with HIV-1
Oct 17, 2008 Ethicon Endo-Surgery Completes Acquisition of SurgRx, Inc.
Oct 15, 2008 Tibotec Begins Enrollment for Phase III Study of Telaprevir, an Investigational Agent, in HCV Patients Who Failed Prior Treatment
Oct 14, 2008 Johnson & Johnson Reports 2008 Third-Quarter Results
Oct 9, 2008 FDA Approves New Injection Site for RISPERDAL(R) CONSTA(R) for Schizophrenia Treatment
Oct 9, 2008 Johnson & Johnson Announces Executive Appointments: Sheri McCoy, Worldwide Chairman, Pharmaceuticals Group, and Alex Gorsky, Worldwide Chairman, Surgical Care Group
Oct 7, 2008 McNeil Consumer Healthcare Supports Voluntary Initiatives To Help Encourage Safe, Effective Use Of Children's Cough And Cold Medicines
Oct 7, 2008 Johnson & Johnson to Host Analyst Meeting to Discuss Third-Quarter Financial Results and Review Pharmaceutical Business
Sep 30, 2008 U.S. District Court in Delaware Enters Final Judgment of Approximately $1.2 Billion to Cordis Corporation on Patents Infringed by Medtronic, Inc. and Boston Scientific Corporation
Sep 18, 2008 Findings from Landmark Study show Ustekinumab Demonstrated Superior Efficacy to Enbrel® (Etanercept) in Treatment of Moderate to Severe Plaque Psoriasis
Sep 17, 2008 Preliminary Data from Experimental Study Demonstrate Increased Mortality in Stroke Patients Treated With Epoetin Alfa
Sep 15, 2008 U.S. District Court in Delaware Reinstates Damage Awards to Cordis Corporation on Patents Infringed by Medtronic, Inc. and Boston Scientific Corporation
Sep 12, 2008 Christine A. Poon Plans Retirement from Johnson & Johnson in Early 2009
Sep 8, 2008 Ortho Biotech Files sNDA for DOXIL® for the Treatment of Advanced Breast Cancer
Sep 8, 2008 VELCADE* for multiple myeloma receives front-line approval in Canada
Sep 8, 2008 VELCADE® (bortezomib) Approved For Previously Untreated Multiple Myeloma
Sep 4, 2008 Clinical Data Indicate that Percutaneous Coronary Intervention with the CYPHER(R) Sirolimus-eluting Coronary Stent Is Comparable to Bypass Surgery in Key Safety Measures in Patients with Diabetes and Multi-Vessel Disease
Sep 2, 2008 First Patient Enrolled in Study Evaluating S.M.A.R.T. (R) Nitinol Self-Expandable Stent System in Leg Disease
Aug 29, 2008 INTELENCETM (etravirine) RECEIVES MARKETING AUTHORISATION IN THE EUROPEAN UNION FOR HIV COMBINATION THERAPY
Aug 28, 2008 Ortho-McNeil Neurologics to Appeal Patent Ruling on RAZADYNE(R)
Aug 28, 2008 The CYPHER(R) Sirolimus-eluting Coronary Stent Outperforms the Taxus(R) Stent in People with Diabetes According to Clinical Data in the Journal of the American College of Cardiology
Aug 27, 2008 CYPHER SELECT(R) Plus Sirolimus-eluting Coronary Stent Receives CE Mark Approval for Treatment of Heart Attacks
Aug 26, 2008 FDA Issues Complete Response Letter for Paliperidone Palmitate for the Treatment of Schizophrenia
Aug 21, 2008 FDA Requires Additional Information on Doribax for Treatment of Hospital-Acquired Pneumonia
Aug 11, 2008 Ethicon Endo-Surgery To Acquire SurgRx
Aug 8, 2008 FDA EXTENDS REVIEW TIMELINE FOR USTEKINUMAB BIOLOGIC LICENSE APPLICATION THREE MONTHS
Aug 5, 2008 Ninety-Six Week Data On Tibotec Investigational NNRTI, TMC278, Presented At AIDS 2008
Aug 1, 2008 Veridex Completes Acquisition of Immunicon Corporation Assets
Jul 30, 2008 Johnson & Johnson (China) Investment Co., Ltd. Acquires Beijing Dabao Cosmetics Co., Ltd.
Jul 30, 2008 Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Submits New Drug Application to FDA for Rivaroxaban
Jul 25, 2008 FDA Grants Pediatric Exclusivity for TOPAMAX®
Jul 16, 2008 FDA Advisory Committee Provides Opinion of DORIBAX(TM) for the Treatment of Hospital-Acquired Pneumonia
Jul 15, 2008 Johnson & Johnson Reports 2008 Second-Quarter Results:
Jul 10, 2008 Johnson & Johnson Announces Commitment To Adopt Revised PhRMA Marketing Code for Responsible Interactions With Healthcare Professionals
Jul 8, 2008 Johnson & Johnson to Host Analyst Conference Call on Second-Quarter Results
Jul 1, 2008 OneTouch® PingTM Glucose Management System Cleared by FDA
Jul 1, 2008 ETHICON Receives Offer from One Equity Partners to Purchase Professional Wound Care Business
Jun 30, 2008 Janssen Announces Launch of Authorized Generic for RISPERDAL(R)
Jun 30, 2008 FDA Approves EVOLENCE®, a New Generation Collagen-Based Facial Filler
Jun 27, 2008 FDA Approves CONCERTA(R) (methylphenidate HCI) Extended-release Tablets for Treatment of ADHD (Attention Deficit Hyperactivity Disorder) in Adults
Jun 18, 2008 Johnson & Johnson Nordic AB Acquires Amic
Jun 17, 2008 FDA Advisory Committee Unanimously Recommends Approval of Ustekinumab for Treatment of Moderate To Severe Plaque Psoriasis
Jun 6, 2008 Johnson & Johnson to Participate in 29th Annual Goldman Sachs Global Healthcare Conference
Jun 5, 2008 Johnson & Johnson Reviews Growth Strategies for Medical Devices & Diagnostics and Consumer Businesses
May 30, 2008 Rivaroxaban Superior to U.S.-Approved Dosing Regimen for Enoxaparin in Reducing Venous Blood Clots after Total Knee Replacement Surgery in Pivotal Phase III Trial
May 29, 2008 Johnson & Johnson to Host Medical Devices & Diagnostics and Consumer Business Review
May 15, 2008 Johnson & Johnson to Participate in Citi's Global Healthcare Conference
May 13, 2008 Biosense Webster Presents ''Complete Ablation Solutions'' to Electrophysiologists at Heart Rhythm 2008
May 13, 2008 State-of-the-Art Cobalt Chromium Bare Metal Stent Now Available in Europe
May 9, 2008 New Data From Phase 3 Study Suggests Tapentadol Immediate Release Effective For Acute Pain From Common Foot Surgery
May 9, 2008 New Study Suggests Tapentadol IR For Acute Pain Is Associated With Improved Gastrointestinal Tolerability Compared To Oxycodone IR
May 9, 2008 Results Of Phase 3 Study Show Tapentadol Ir Relieves Acute Pain And Offers Favorable Gastrointestinal Tolerability Profile
May 7, 2008 Johnson & Johnson to Provide Webcast Presentation of Tapentadol Phase 3 Clinical Data Presented at American Pain Society's Annual Meeting
Apr 29, 2008 Johnson & Johnson to Participate in Deutsche Bank Health Care Conference
Apr 25, 2008 Johnson & Johnson to Participate in Morgan Stanley Conference
Apr 24, 2008 Johnson & Johnson Announces Dividend Increase of 10.8%
Apr 22, 2008 Johnson & Johnson to Webcast Annual Meeting of Shareholders
Apr 15, 2008 Johnson & Johnson Reports 2008 First-Quarter Results:
Apr 11, 2008 Ortho Biotech Oncology Research & Development Unites Johnson & Johnson Biopharmaceutical Oncology R&D Assets
Apr 9, 2008 NEJM Study Demonstrates Carotid Stenting with Embolic Protection is Comparable to Surgery
Apr 8, 2008 Johnson & Johnson to Host Analyst Conference Call on First-Quarter Results
Apr 4, 2008 Data From Ortho Biotech-Sponsored Studies To Be Presented At National Kidney Foundation 2008 Spring Clinical Meetings
Apr 1, 2008 First New NNRTI in Nearly a Decade to Benefit Canadians with HIV/AIDS
Mar 30, 2008 Three Year Follow-up Data Suggest Better Outcomes Were Maintained with the CYPHER(R) Sirolimus-Eluting Coronary Stent Compared to Brachytherapy in Patients with In-Stent Reblockage
Mar 28, 2008 Ortho-Clinical Diagnostics Receives FDA Approval for New HIV Test
Mar 27, 2008 Clinical Trial Begins for Innovative Drug-Eluting Stent with Unique Reservoir Technology
Mar 27, 2008 Ethicon Endo-Surgery Submits Application to FDA for Approval of the Sedasys™ System - The First Computer-Assisted Personalized Sedation System
Mar 21, 2008 Relief "In Sight" For Allergy Sufferers
Mar 19, 2008 Centocor, Inc. And Schering-Plough Submit Application Requesting Approval Of Golimumab In Europe For The Treatment Of Rheumatoid Arthritis, Psoriatic Arthritis And Ankylosing Spondylitis
Mar 18, 2008 FDA Issues Approvable Letter for Ceftobiprole for Treatment of Complicated Skin Infections
Mar 17, 2008 Cordis Corporation Receives U.S. Food and Drug Administration Clearance for S.M.A.R.T. Nitinol Stent Transhepatic Biliary System for 120 mm and 150 mm Lengths
Mar 17, 2008 Ortho Biotech Statement on U.S. Food and Drug Administration Oncologic Drugs Advisory Committee Vote
Mar 13, 2008 Johnson & Johnson to Participate in the 28th Annual Cowen & Company Health Care Conference
Mar 11, 2008 Totality of Available Data Reaffirms PROCRIT® (Epoetin alfa) Safe and Effective When Used Appropriately As Labeled to Treat Chemotherapy-Induced Anemia
Mar 11, 2008 Johnson & Johnson to Participate in Lehman Brothers Eleventh Annual Global Healthcare Conference
Mar 7, 2008 Ortho Biotech Modifies Prescribing Information for PROCRIT® (Epoetin alfa)
Mar 6, 2008 FDA Extends Review Timeline for Additional Indication for Antibiotic DORIBAX(TM)
Feb 27, 2008 FDA CLEARS CELLSEARCH™ CIRCULATING TUMOR CELL TEST
Feb 27, 2008 DePuy to Host Analyst Meeting
Feb 12, 2008 PRICARA™ RECALLS 25 mcg/hr DURAGESIC® (fentanyl transdermal system) CII PAIN PATCHES
Feb 7, 2008 New 48-Week Efficacy and Safety Data Presented for Intelencetm (Etravirine) As Part of HIV Combination Therapy
Feb 4, 2008 Promising Phase 3 Data for Ustekinumab (Cnto 1275) in Long-Term Improvement of Chronic Plaque Psoriasis
Feb 4, 2008 Centocor Announces Ustekinumab Biologic License Application Accepted For Filing By FDA
Feb 4, 2008 Study Suggests Risperidone Long-Acting Injection Combined with Standard Treatment Helped Delay Time to Relapse in Patients with Bipolar Disorder
Jan 23, 2008 New Drug Application Submitted to FDA for Investigational Analgesic Tapentadol Immediate Release Tablets
Jan 22, 2008 Johnson & Johnson Reports Fourth-Quarter and Full-Year 2007 Results
Jan 18, 2008 FDA Approves INTELENCE(TM) (etravirine) for HIV Combination Therapy
Jan 15, 2008 Johnson & Johnson to Review Fourth-Quarter and Full-Year 2007 Financial Results
Jan 14, 2008 IONSYS™, the highly innovative needle-free system for the management of acute post-operative pain, available in Germany, the UK and Ireland
Jan 7, 2008 Court of Appeals Upholds Verdicts in Favor of Cordis Corporation on Patents Infringed by Medtronic, Inc. and Boston Scientific Corporation
Dec 21, 2007 Supplemental New Drug Application for PREZISTA™ Submitted to U.S. Food and Drug Administration
Dec 21, 2007 Centocor Inc., Schering-Plough Corporation Revise Agreement Covering REMICADE®, Golimumab
Dec 21, 2007 Submission of Marketing Authorisation Application for VELCADE® (bortezomib) in Europe
Dec 12, 2007 INVEGA™ Shows Favorable Long-Term Safety Profile in a One Year Study of Patients With Schizophrenia
Dec 10, 2007 Three Phase III Trials Show Rivaroxaban Outperformed Enoxaparin in Preventing Venous Thromboembolism After Major Orthopedic Surgery
Dec 8, 2007 Pivotal Phase III Data Showed Rivaroxaban Was Statistically Superior to Enoxaparin in Preventing Venous Thromboembolism (VTE) in Patients Following Hip Replacement Surgery
Dec 4, 2007 Centocor and Janssen-Cilag announced the submission of the US and European filings for ustekinumab (CNTO 1275) for the treatment of adult patients with chronic moderate to severe plaque psoriasis.
Nov 16, 2007 FDA Approves the Allergy Treatment Zyrtec® for Use Without a Prescription
Nov 15, 2007 Johnson & Johnson Announces Changes to Accelerate Growth
Nov 9, 2007 New Phase III Trial Results for Rivaroxaban to be Presented at the 49th Annual Meeting of the American Society of Hematology
Nov 6, 2007 Johnson & Johnson to Present at the Credit Suisse 2007 Healthcare Conference
Nov 5, 2007 Pooled Analysis Of Long-Term Data Suggests CYPHER® Sirolimus-Eluting Coronary Stent Provides Sustained Clinical Benefits In Patients With Coronary Artery Disease Compared To Bare Metal Stents
Nov 1, 2007 Johnson & Johnson to Host Analyst Meeting to Discuss Three Late-Stage Pipeline Compounds Presented at American College of Rheumatology (ACR) Conference
Oct 29, 2007 Johnson & Johnson Pharmaceutical Research & Development Submits New Drug Application for Paliperidone Palmitate
Oct 26, 2007 New Study of Concerta(R) Showed Significant Improvement of ADHD Symptom Management in Adults Compared to Placebo
Oct 23, 2007 Adoption of Drug-Eluting Stents Associated With Lower Health Care Costs and Improved Clinical Outcomes
Oct 23, 2007 Next Generation New Devices to Treat Clogged Neck Arteries Launched in U.S. and Europe
Oct 22, 2007 New Long-Term Data Suggest Clinical Differences in Safety and Efficacy Between CYPHER® Sirolimus-Eluting Coronary Stent and Taxus Stent
Oct 21, 2007 New Study Shows Excellent Outcomes for CYPHER® Sirolimus-Eluting Coronary Stent in Treatment of Completely Blocked Coronary Arteries
Oct 17, 2007 Cordis Corporation Announces Clinical Studies And Events At TCT 2007
Oct 16, 2007 Johnson & Johnson Launches Global Diabetes Institute to Provide State-of-The- Art Education, Training to Health Professionals
Oct 16, 2007 Johnson & Johnson Reports 2007 Third-Quarter Results: Sales of $15.0 Billion Increased 12.7%; EPS was $.88, Including Special Charges; Excluding Special Charges, EPS was $1.06 *
Oct 15, 2007 FDA Approves DORIBAX™ for the Treatment of Complicated Intra-Abdominal and Complicated Urinary Tract Infections
Oct 13, 2007 INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients
Oct 11, 2007 McNeil Consumer Healthcare Is Voluntarily Withdrawing Infants' Cough And Cold Products: CONCENTRATED TYLENOL® INFANTS' DROPS PLUS COLD, CONCENTRATED TYLENOL® INFANTS' DROPS PLUS C
Oct 10, 2007 Johnson & Johnson to Host Analyst Meeting to Discuss Third-Quarter Financial Results and Review Its Medical Device & Diagnostics Business
Oct 9, 2007 New HARMONIC FOCUS™ Provides Advantages in Surgical Efficiency, Performance and Patient Outcomes
Oct 8, 2007 New Data Show Ceftobiprole as Effective as Combination Therapy in Treating Patients with Diabetic Foot Infections
Oct 8, 2007 Topline Findings from Comparative Analysis of INVEGA(TM) and Quetiapine in Schizophrenia to be Postered at the 20th Annual U.S. Psychiatric and Mental Health Congress
Oct 3, 2007 Ortho-Clinical Diagnostics Introduces Improved Sensitivity Troponin I Assay To Help Diagnose Heart Attack, Heart Damage
Sep 27, 2007 Statement of DePuy Orthopaedics, Inc. Regarding Agreement with U.S. Attorney's Office
Sep 25, 2007 Pivotal Ustekinumab (CNTO 1275) Phase 3 Data to Debut at World Congress of Dermatology Meeting
Sep 20, 2007 FDA Accepts New Drug Application For Priority Review Of Investigational HIV Treatment TMC125
Sep 20, 2007 Johnson Statement on Litigation with the American Red Cross
Sep 18, 2007 New Phase 3 Study In Treatment-Naïve Adults With HIV Evaluates Efficacy And Safety Of Once-Daily PREZISTA™/Ritonavir Vs. Kaletra® As Part Of HIV Combination Therapy
Sep 18, 2007 New Data Show Ceftobiprole as Effective as Combination Therapy in Treating Patients With Complicated Skin Infections, Including MRSA
Sep 18, 2007 New Data Show Doripenem as Effective as Commonly Used Therapies in Treating Hospital-Acquired Pneumonias
Sep 17, 2007 FDA Approves LEVAQUIN® Short-Course Therapy for Treatment of Complicated Urinary Tract Infections and Acute Pyelonephritis
Sep 13, 2007 Largest Study To Date Finds Drug-Eluting Stents And Bare-Metal Stents Yield Similarly Low Mortality Rates
Sep 12, 2007 Ortho Biotech Reiterates Confidence in PROCRIT® (Epoetin alfa) Safety and Efficacy When Used According to Label
Sep 11, 2007 Ortho Biotech Reiterates Confidence in PROCRIT® (Epoetin alfa) Safety and Efficacy When Used According to Label
Sep 5, 2007 Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
Sep 4, 2007 Johnson & Johnson to Participate in Bear Stearns 20th Annual Healthcare Conference
Sep 4, 2007 Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
Sep 3, 2007 Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
Aug 22, 2007 FDA Approves RISPERDAL® to Treat Adolescents With Schizophrenia and Children and Adolescents With Bipolar Mania
Aug 8, 2007 Johnson & Johnson Statement on Civil Complaint Against The American National Red Cross and Commercial Licensees
Jul 31, 2007 Johnson & Johnson Plans to Improve Overall Cost Structure, While Continuing to Invest in Opportunities for Sustained Profitable Growth
Jul 19, 2007 Ortho-McNeil, Inc., Settles Patent Infringement Litigation Against Par/Kali
Jul 18, 2007 New Drug Application for Investigational HIV Treatment TMC125 Submitted to U.S. Food and Drug Administration
Jul 17, 2007 Johnson & Johnson Reports 2007 Second-Quarter Results: Sales Increase of 13.2% and EPS increase of 10.5% Versus a Year Ago; Excluding Special Charges in 2006, EPS increased 7.1%*
Jul 17, 2007 FDA Approves First Gene-Based Test To Detect The Spread Of Breast Cancer Into Lymph Nodes
Jul 11, 2007 Johnson & Johnson to Host Analyst Conference Call on Second-Quarter Results
Jul 9, 2007 Johnson & Johnson Announces $10 Billion Share Repurchase Program
Jul 8, 2007 Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Jul 6, 2007 TMC125 Demonstrates Significant Efficacy in Treatment-Experienced Patients with NNRTI Resistance in Phase III trials
Jul 6, 2007 New PREZISTA® Phase III Study meets primary objective of non-inferiority and secondary objective of superiority in virologic response vs. KALETRA® in treatment-experienced HIV patients
Jun 28, 2007 INVEGA™ Receives Marketing Authorization In European Union For Treatment Of Schizophrenia
Jun 28, 2007 World Council of Optometry Awards ACUVUE(R) ADVANCE(TM), ACUVUE(R) OASYS(TM) Brands With Global Seal of Acceptance for UV Absorbing Contact Lenses
Jun 21, 2007 FDA Issues Approvable Letter for RISPERDAL(R) to Treat Adolescents with Schizophrenia and Children and Adolescents with Bipolar Mania
Jun 14, 2007 Johnson & Johnson Invites Nominations for the 2008 Dr. Paul Janssen Award for Biomedical Research
Jun 14, 2007 Cordis Corporation Resolves Corporate Warning Letter
Jun 12, 2007 William D. Perez of Wm. Wrigley Jr. Company Appointed to Johnson & Johnson Board of Directors
Jun 7, 2007 New Balloon Catheter Available Worldwide for Carotid and Renal Angioplasty Procedures
Jun 7, 2007 Johnson & Johnson Highlights Growth Strategies for Pharmaceutical and Consumer Businesses
Jun 6, 2007 New Drug Application Submitted for Investigational Antibiotic Doripenem
Jun 6, 2007 VISTAKON(R) Launches Electronic Contact Lens Reminder Service to Help Improve Contact Lens Compliance
Jun 4, 2007 New Study Suggests Better Patient Outcomes with CYPHER(R) Sirolimus-Eluting Coronary Stent than with Taxus Stent in Real-World Clinical Settings
May 29, 2007 Johnson & Johnson To Host Pharmaceutical and Consumer Business Review
May 22, 2007 CYPHER(R) Sirolimus-Eluting Coronary Stent Had Similar Results to Bypass Surgery and Better Outcomes Than Bare Metal Stents in Subgroup Analysis of Diabetic Patients With Multivessel Coronary Disease
May 21, 2007 Johnson & Johnson to Participate in Bank of America 2007 Health Care Conference
May 18, 2007 New Drug Application Submitted For Novel Investigational Antibiotic Ceftobiprole
May 16, 2007 Johnson & Johnson to Participate in Citigroup's Global Healthcare Conference
May 16, 2007 Cordis To Host Analyst Meeting At EuroPCR 2007
May 11, 2007 Southern District Court of New York Rules Patent for ACIPHEX® Enforceable
May 7, 2007 Conor Medsystems, LLC Reports COSTAR II Pivotal Drug-Eluting Stent Trial Conclusions
May 4, 2007 Ortho-Clinical Diagnostics, Inc. Issues Voluntary, Nationwide Recall for Cardiac Marker
Apr 27, 2007 Johnson & Johnson to Participate in Morgan Stanley Conference
Apr 26, 2007 Johnson & Johnson Announces Dividend Increase of 10.7%
Apr 19, 2007 Johnson & Johnson to Host Annual Meeting of Shareholders
Apr 19, 2007 Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Breaks Ground on New Facility
Apr 17, 2007 Johnson & Johnson Reports 2007 First-Quarter Results: Sales Increase of 15.7% and EPS of $.88 Versus $1.10 a Year Ago; Excluding Special Items, EPS was $1.16, an increase of 17.2% *
Apr 11, 2007 Johnson & Johnson to Host Analyst Conference Call on First-Quarter Results
Mar 26, 2007 Two-Year Patient Registry Results Support Safety and Efficacy of CYPHER(R) Sirolimus-Eluting Coronary Stent in 'Real World' Uses
Mar 20, 2007 Cordis Corporation to Emphasize Commitment to Interventional Cardiology at ACC.07
Mar 13, 2007 Johnson & Johnson to Participate in Lehman Brothers Tenth Annual Global Healthcare Conference
Mar 12, 2007 Johnson & Johnson Receives Subpoenas
Mar 7, 2007 Johnson & Johnson to Participate in the 27th Annual Cowen & Company Health Care Conference
Feb 12, 2007 Johnson & Johnson Statement on Voluntary Disclosure
Feb 1, 2007 Johnson & Johnson Completes Acquisition of Conor Medsystems, Inc.
Jan 23, 2007 Johnson & Johnson Reports Fourth-Quarter and Full-Year 2006 Results
Jan 17, 2007 Johnson & Johnson to Review Fourth-Quarter and Full-Year 2006 Financial Results
Dec 20, 2006 Johnson & Johnson Completes Acquisition of Pfizer Consumer Healthcare
Dec 12, 2006 Johnson & Johnson Acquisition of Pfizer Consumer Healthcare Receives Clearance from U.S. Federal Trade Commission (FTC)
Dec 11, 2006 Analysis From Real-World Drug Administration Data Suggests Lower Drug Cost For PROCRIT(R) (Epoetin Alfa) in Outpatient Setting
Nov 27, 2006 Winter Sun's Rays Can Be Damaging to Eyes
Nov 16, 2006 Johnson & Johnson Announces Definitive Agreement to Acquire Conor Medsystems, Inc.
Oct 24, 2006 Cordis Corporation To Study Impact Of Contributing Factors To Stent Thrombosis In Expansion Of 30,000-Stent Patient Registry
Oct 24, 2006 U.S. District Court Grants Request for Preliminary Injunction to Ortho-McNeil Neurologics, Inc. for TOPAMAX(R)
Oct 17, 2006 Johnson & Johnson Reports 2006 Third-Quarter Results: Sales Increase of 7.9% and EPS of $.94 Versus $.85 a Year Ago; Excluding In-Process Research and Development Charges, EPS Increased 15.3% *
Oct 16, 2006 Cordis to Host Analyst Meeting at TCT Conference
Oct 16, 2006 U.S. District Court Upholds RISPERDAL(R) Patent
Oct 10, 2006 Johnson & Johnson to Host Analyst Conference Call on Third-Quarter Results
Oct 6, 2006 Robert J. Darretta to Retire as Vice Chairman and CFO of Johnson & Johnson
Sep 28, 2006 As U.S. Population Swells to 300 Million, New Survey Examines The Evolution of Motherhood
Sep 13, 2006 Johnson & Johnson to Participate in Merrill Lynch Conference
Sep 12, 2006 RNAi Pioneer Craig Mello Named Inaugural Winner of the Dr. Paul Janssen Award for Biomedical Research
Sep 7, 2006 Johnson & Johnson to Participate in the Bear Stearns 19th Annual Health Care Conference
Aug 29, 2006 Johnson & Johnson to Host Medical Devices & Diagnostics Business Review
Jul 25, 2006 VISTAKON to Introduce New 1-DAY ACUVUE(R) MOIST(TM) Brand Contact Lenses In U.S. - A Breakthrough in Comfort
Jul 21, 2006 Update on FDA Psychopharmacologic Drugs Advisory Committee Meeting for Sept. 7 on Paliperidone Extended-Release Tablets
Jul 18, 2006 Johnson & Johnson Reports 2006 Second-Quarter EPS Increase of 10.5% on Sales Increase of 4.7%
Jul 12, 2006 Investigational Drug Paliperidone ER Significantly Delayed Symptom Recurrence In Clinical Study of Patients With Schizophrenia
Jul 12, 2006 Johnson & Johnson to Host Analyst Meeting to Discuss Second-Quarter Financial Results; Review Pharmaceuticals Business/Pipeline and the Planned Acquisition of Pfizer Consumer Healthcare
Jul 11, 2006 New Survey Reveals Many Contact Lens Wearers Find Their Lenses Uncomfortable, Disruptive When Experiencing Eye-Allergy Symptoms
Jul 6, 2006 2006 NBA Champion Alonzo Mourning Raises Awareness About Kidney Disease
Jun 30, 2006 Janssen Pharmaceutica Announces Collaboration with Vertex Pharmaceuticals to Develop and Commercialize VX-950 for Treatment of Hepatitis C
Jun 26, 2006 Johnson & Johnson to Acquire Pfizer Consumer Healthcare; Combination Creates World's Premier Consumer Health Care Company
Jun 23, 2006 American Optometric Association Awards ACUVUE ADVANCE, ACUVUE OASYS Brands With Seal of Acceptance for UV Absorbing Contact Lenses
Jun 8, 2006 Johnson & Johnson to Participate in Goldman Sachs Conference
Jun 1, 2006 Update On Regulatory Filing Plans for Investigational Compound Trabectedin in Soft Tissue Sarcoma
May 23, 2006 Clinical Study of Investigational Drug Paliperidone ER Demonstrated Efficacy and Tolerability in the Treatment of Patients With Schizophrenia
May 16, 2006 Physicians Now Have a New Treatment Option for Patients With a Common Vascular Disease Affecting the Legs
May 11, 2006 District Court Issues Two Decisions Regarding Patent Litigation Between Cordis Corporation and Boston Scientific
May 11, 2006 Johnson & Johnson to Participate in the Banc of America Securities Health Care Conference 2006
May 10, 2006 Pharmaceutical Operating Companies of Johnson & Johnson Continue Patient Assistance for Eligible Medicare Beneficiaries
May 9, 2006 ETHICON, Inc. Completes Acquisition of Vascular Control Systems, Inc.
May 5, 2006 Janssen-Cilag Submits Marketing Authorization Application in Europe for New Treatment for Schizophrenia
Apr 27, 2006 Johnson & Johnson to Participate in Morgan Stanley Conference
Apr 27, 2006 Johnson & Johnson Announces Dividend Increase of 13.6%
Apr 24, 2006 Johnson & Johnson to Host Annual Meeting of Shareholders
Apr 18, 2006 Johnson & Johnson Reports 2006 First-Quarter EPS Rose 17.0% on Sales Increase of 1.2%
Apr 11, 2006 Johnson & Johnson to Host Analyst Conference Call on First-Quarter Results
Mar 31, 2006 Ortho-Clinical Diagnostics Issues a Voluntary Product Recall for VITROS(R) Immunodiagnostic Products Signal Reagent
Mar 28, 2006 Johnson & Johnson Presents $100,000 Grant for SF Disaster Preparedness & Neighborhood Emergency Response Training (NERT) Program
Mar 23, 2006 Johnson & Johnson Consumer France SAS to Acquire Groupe Vendome SA
Mar 20, 2006 Increased Use of Computers, Portable Gadgets Leading to More Visual Fatigue And Discomfort
Mar 8, 2006 Johnson & Johnson Announces Stock Repurchase Program
Mar 1, 2006 Johnson & Johnson To Participate In The 26th Annual Cowen & Company Health Care Conference
Feb 23, 2006 Silver Medalists Belbin & Agosto See Gold With ACUVUE® OASYS™ Brand
Feb 17, 2006 Johnson & Johnson Completes Acquisition of Animas Corporation
Feb 13, 2006 Charles Prince of Citigroup Elected to Johnson & Johnson Board of Directors
Feb 1, 2006 Johnson & Johnson to Participate in Merrill Lynch Conference
Jan 30, 2006 European Commission Approves IONSYS(TM) (Fentanyl HCl Iontophoretic Transdermal System)
Jan 25, 2006 Johnson & Johnson Statement Regarding Guidant Corporation
Jan 24, 2006 Johnson & Johnson Reports Full-Year and Fourth-Quarter 2005 Results
Jan 19, 2006 DePuy Orthopaedics Concludes Acquisition of Hand Innovations LLC
Jan 18, 2006 Johnson & Johnson to Review Fourth-Quarter and Full-Year 2005 Financial Results
Jan 17, 2006 Johnson & Johnson Statement Regarding Guidant Corporation Acquisition
Jan 13, 2006 Guidant Corporation and Johnson & Johnson Announce New Definitive Acquisition Agreement
Jan 11, 2006 Guidant Corporation and Johnson & Johnson Announce New Definitive Acquisition Agreement
Jan 8, 2006 Johnson & Johnson Reaffirms Commitment to Guidant Acquisition
Jan 3, 2006 Scios Submits Interim Report to FDA on NATRECOR®(nesiritide) PROACTION Trial
Dec 28, 2005 Johnson & Johnson and Guidant Corporation Proposed Merger Registration Statement Declared Effective
Dec 21, 2005 Personal Products Company Completes Acquisition of REMBRANDT(R) Brand From The Gillette Company
Dec 16, 2005 Johnson & Johnson Announces Definitive Agreement to Acquire Animas Corporation, an Insulin Delivery Company
Dec 14, 2005 Potential New Treatment for Patients with Schizophrenia
Dec 8, 2005 Contact Lens Made With New Silicone Hydrogel Material May Help Reduce Most Frequently Reported Lens Problems, Study Shows
Dec 6, 2005 Johnson & Johnson Files Form S-4 Registration Statement Regarding Acquisition of Guidant Corporation
Dec 1, 2005 ALZA Corporation Modifies U.S. Clinical Development Program for OROS Hydromorphone (AP-77)
Nov 30, 2005 New Drug Application Submitted for Potential New Treatment for Schizophrenia
Nov 28, 2005 ALZA Corporation Resubmits U.S. New Drug Application for IONSYS(TM) (Fentanyl HCl Patient-Activated Transdermal System)
Nov 22, 2005 Johnson & Johnson to Participate in Fifth Annual Merrill Lynch Med Tech Fundamentals Conference
Nov 15, 2005 Johnson & Johnson and Guidant Corporation Announce Revised Acquisition Agreement with Net Value of $19 Billion
Nov 10, 2005 Study Finds Patients with Moderate to Severe Chronic Kidney Disease Go Undiagnosed
Nov 7, 2005 Johnson & Johnson Statement Regarding Guidant Corporation Civil Suit
Nov 3, 2005 Johnson & Johnson to Participate in CIBC World Markets Sixteenth Annual Health Care Conference
Nov 2, 2005 Johnson & Johnson Receives FTC Clearance of Proposed Acquisition of Guidant Corporation and Provides Update on Transaction in Light of Guidant Recall Events
Oct 26, 2005 Tibotec Announces U.S. Expanded Access Program for TMC114
Oct 24, 2005 Personal Products Company to Acquire Rembrandt Brand from The Gillette Company
Oct 18, 2005 Johnson & Johnson Reports 2005 Third-Quarter EPS Rose 11.5% on Sales Increase of 6.6%
Oct 14, 2005 European Authorities Recommend Approval for IONSYS(TM)
Oct 12, 2005 Johnson & Johnson to Host Analyst Conference Call on Third-Quarter Results
Sep 28, 2005 Cordis Corporation Acquires LuMend, Inc.
Sep 26, 2005 Basketball Star Alonzo Mourning Spreads the Word About Kidney Disease
Sep 22, 2005 Head-to-Head Study of Treatments for Chemotherapy-Related Anemia Published in The Oncologist
Sep 7, 2005 Johnson & Johnson to Participate in the 18th Annual Bear Stearns 2005 Health Care Conference
Sep 2, 2005 Johnson & Johnson Advised by Canadian Competition Bureau on Proposed Acquisition of Guidant Corporation
Aug 25, 2005 Johnson & Johnson Announces European Commission Clearance of Guidant Acquisition
Aug 11, 2005 Newly Published Study Evaluates Extended Dosing Regimens of PROCRIT® (Epoetin alfa) as Maintenance Treatment for Patients with Anemia from Chronic Kidney Disease
Aug 2, 2005 Johnson & Johnson Adopts PhRMA Guidelines on Direct-to-Consumer Advertising
Jul 26, 2005 Johnson & Johnson Becomes Official Partner of Beijing 2008 Olympic Games, Torino 2006 Olympic Winter Games, USOC and National Olympic Teams
Jul 20, 2005 Scios Inc. Receives Subpoena on NATRECOR(R) (Nesiritide)
Jul 19, 2005 Scios Inc. Announces Redemption of 5.50% Debentures Due August 2009
Jul 19, 2005 Johnson & Johnson Reports 2005 Second-Quarter Sales Increase of 11.1% and EPS of $.89 Versus $.82 a Year Ago; Excluding In-Process Research and Development Charges and Revised Tax Impact of American Jobs Creation Act, EPS Increased 13.4%*
Jul 12, 2005 Johnson & Johnson to Host Analyst Conference Call on Second Quarter Results
Jul 1, 2005 Cordis to Ask Judge to Overturn Patent Verdict
Jun 30, 2005 Cordis Endovascular Launches PALMAZ(R) BLUE(TM) Transhepatic Biliary Cobalt Chromium Stent in U.S.
Jun 30, 2005 Johnson & Johnson Completes Acquisition of Peninsula Pharmaceuticals, Inc.
Jun 21, 2005 Jury Finds Cordis Patents Infringed by Boston Scientific Stents
Jun 17, 2005 Johnson & Johnson Statement Regarding Guidant Transaction
Jun 9, 2005 Cordis Corporation to Appeal Court Ruling
Jun 3, 2005 Johnson & Johnson Completes Acquisition of CLOSURE Medical Corporation
Jun 2, 2005 New Online Greeting Card Promotes Awareness of Chronic Kidney Disease During Hispanic Health Month
Jun 2, 2005 World-Renowned Chef and Cancer Survivor Biba Caggiano Visits Long Island Hospitals to Help Cancer Patients Find Strength for Living
May 24, 2005 Johnson & Johnson Statement Regarding Guidant Transaction
May 19, 2005 Johnson & Johnson to Host Pharmaceutical Research and Development Review
May 18, 2005 CYPHER(R) Sirolimus-eluting Coronary Stent Clinical Data to Be Featured at 2005 EuroPCR
May 17, 2005 Online Greeting Card Series Honors Women Affected by Chronic Kidney Disease
May 15, 2005 Head-to-Head Study of Treatments for Chemotherapy-Related Anemia Found Patients Treated With Procrit(R) Demonstrated Greater Increase in Red Blood Cell Levels, Required Less Transfused Blood
Apr 29, 2005 Johnson & Johnson to Participate in Morgan Stanley Conference
Apr 29, 2005 World-Renowned Chef and Cancer Survivor Biba Caggiano Shares Ingredients for Helping Cancer Patients Find Strength for Living
Apr 28, 2005 Johnson & Johnson Announces Dividend Increase of 15.8%
Apr 27, 2005 New ACUVUE(R) ADVANCE(TM) Brand Contact Lenses for ASTIGMATISM Offer Consistent All-Day Vision, Comfort in The 'Blink Of An Eye'
Apr 26, 2005
Apr 22, 2005 Johnson & Johnson Proposed Acquisition of Guidant Corporation Enters Second Phase Review by European Commission
Apr 21, 2005 Johnson & Johnson to Host Annual Meeting of Shareholders
Apr 20, 2005 CYPHER(R) Sirolimus-Eluting Coronary Stent Receives FDA Approval for MRI Scans Immediately Following Implantation
Apr 19, 2005 Johnson & Johnson - The World's Most Broadly Based Health Care Company Reports 2005 First-Quarter EPS Rose 16.9% on Sales Increase of 11.0%
Apr 19, 2005 Johnson & Johnson Announces Agreement to Acquire Peninsula Pharmaceuticals, Inc.
Apr 13, 2005 Johnson & Johnson to Host Analyst Conference Call on First Quarter Results
Apr 5, 2005 U.S. Pharmaceutical and Biotechnology Companies of Johnson & Johnson Participate in Partnership for Prescription Assistance
Apr 4, 2005 Johnson & Johnson Completes Acquisition of TransForm Pharmaceuticals, Inc.
Mar 30, 2005 DePuy Orthopaedics, Inc. Receives Subpoena
Mar 24, 2005 Johnson & Johnson and Guidant Corporation Proposed Merger Registration Declared Effective
Mar 14, 2005 Michael M.E. Johns, M.D. of Emory University Nominated for Election to the Johnson & Johnson Board of Directors
Mar 9, 2005 Johnson & Johnson to Acquire TransForm Pharmaceuticals
Mar 6, 2005 Arts II Clinical Study Shows Promising Results for the Cypher(R) Sirolimus-Eluting Coronary Stent In Patients With Multi-Vessel Disease
Mar 6, 2005 REALITY Trial Data Suggest Drug-Eluting Stents Differ Significantly in Rate of Blood Clot Formation-Stent Thrombosis
Mar 4, 2005 Johnson & Johnson and CLOSURE Medical Corporation Announce Acquisition Agreement
Mar 4, 2005 Multimedia Available: Basketball Star Alonzo Mourning Reaches Out to Fellow Kidney Disease Patients with New Series of Online Greeting Cards
Mar 1, 2005 Cordis to Host Analyst Meeting to Review REALITY Trial Results
Feb 28, 2005 Multimedia Available: KidneyResource.com: A New Internet Gateway to Science-Based Information About Chronic Kidney Disease
Feb 24, 2005 CYPHER(R) Sirolimus-Eluting Coronary Stent to Be Featured in Late-Breaking Clinical Trial Presentations at 2005 American College of Cardiology Scientific Session
Feb 24, 2005 CYPHER(R) Sirolimus-Eluting Coronary Stent to Be Featured in Late-Breaking Clinical Trial Presentations at 2005 American College of Cardiology Scientific
Feb 18, 2005 Johnson & Johnson and Guidant Corporation Will Respond to Federal Trade Commission's Request For Information
Feb 14, 2005 Stories of Survival and Hope Mark the One Million Patient Milestone For the CYPHER(R) Sirolimus-eluting Coronary Stent
Feb 3, 2005 Johnson & Johnson to Participate in Merrill Lynch Conference
Jan 25, 2005 Johnson & Johnson - The World's Most Broadly Based Health Care Company 2004 Fourth-Quarter Sales Increased 13.3% Tax Impact of American Jobs Creation Act Reduced Fourth-Quarter Earnings 2004 Full Year EPS Rose 18.3% on Sales Increase of 13.1%
Jan 24, 2005 Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Completes Submission of Tipifarnib NDA to FDA Continuous Marketing Application Pilot-1 Program
Jan 21, 2005 Health Authorities Reviewing Safety Data from Investigational Study Involving REMINYL(R) (galantamine hydrobromide)
Jan 18, 2005 Johnson & Johnson To Review Fourth-Quarter Results
Jan 12, 2005 Christine A. Poon Appointed a Vice Chairman of Johnson & Johnson